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Abstract 
The work presented in the following thesis dissertation examines the regulation of 
phosphotyrosine (pY) signaling, an essential cellular process that relies on the activity of three 
major protein classes: Tyrosine kinases (TKs) which induce pY signaling by phosphorylating 
tyrosine residues on substrate proteins, Protein tyrosine phosphatases (PTPs) which suppress 
pY signaling by removing phosphate moieties from tyrosine phosphorylated proteins and Src-
Homology 2 (SH2) containing proteins which bind to tyrosine phosphorylated proteins and 
connect them to downstream signaling pathways.  The effects of kinase localization, temporal 
changes in kinase activation, SH2 protein concentration, and negative feedback from 
downstream signaling pathways are all examined by the research presented here.  This is 
accomplished by exploiting the Epidermal Growth Factor Receptor (EGFR), a clinically 
important transmembrane TK, and its SH2 protein mediated downstream pathways.  Using 
EGFR signaling as a tool, this dissertation research attempts to define innate properties of pY 
signaling systems which are broadly applicable and advance our understanding of the field. 
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Assessing Extracellular Signals and Phosphotyrosine Dynamics 
Multicellular organisms have evolved a number elegant mechanisms capable of interpreting the 
extracellular environment and translating into the language of cellular signaling (1).  Typically 
extracellular ligands bind to cellular receptors, inducing allosteric changes within proteins which 
either directly induce enzymatic activity, or promote interactions which lead to receptor 
activation and/ or the recruitment of downstream enzyme effectors.  These signal traducers 
include, but are not limited to G-protein coupled receptors, steroid hormone receptors, immune 
cell receptors, and receptor tyrosine kinases (RTKs).  Each of these transducers classes 
encompasses a large number proteins which activate numerous molecular pathways, a 
complete discussion of which is well beyond the scope of any individual thesis project.  
Protein signaling systems involved in inducing and regulating post-translational modification 
(PTMs) such as phosphorylation, acetylation, methylation and to potentially sumoylation and 
ubiquinylation can be distilled into three major components; Writers, Readers and Erasers.  
Writers function to conjugate PTMs to their target proteins, typically inducing signal 
transduction. Readers contain PTM-binding modular domains which translate PTMs into 
downstream signaling. Erasers remove PTMs, dampening or even preventing signaling from 
specific PTM mediated pathways(2).  Put simply, total signal output is a function of the balance 
between Writer and Eraser activity, and Reader binding.  The work presented here focuses 
phosphotyrosine (pY) mediated signaling in which signal output is defined by the interplay 
between tyrosine kinases (Writers), protein tyrosine phosphatases (Erasers) and Src-Homology 
2 (SH2) domain containing proteins (Readers) (Figure i 1). Specifically we focus on how the 
intracellular concentration, localization and activities of each component can modify signal 
output in unexpected ways.    
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Figure i 1. Writer, Reader, Eraser model of phosphotyrosine signaling. Phosphotyrosine 
signaling is a classic example of the “writer, reader, eraser” signaling paradigm originally 
devised for chromatin modification signaling.  Tyrosine kinase writers catalyze the transfer of the 
-PO4 from ATP to a tyrosine residue on substrate proteins.  These phosphorylated tyrosines 
function as docking sites for SH2 domain containing reader proteins which translate the 
phosphorylation of specific tyrosines into specific downstream signaling pathways. 
Phosphotyrosine signals are tempered by protein tyrosine phosphates (PTP) which catalyze the 
removal of phosphotyrosine residues from substrate proteins not bound to SH2 domains. The 
balance of kinase and PTP activities define the level protein tyrosine phosphorylation.  Figure 
adapted B. J. Mayer, Perspective: Dynamics of receptor tyrosine kinase signaling complexes. 
FEBS Lett. 586, 2575–9 (2012). 
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Tyrosine Kinases 
Receptor tyrosine kinases are transmembrane proteins belonging to the larger family of 
approximately 90 tyrosine kinases (TKs) and 43 tyrosine kinase-like proteins (3–5). These 
proteins can be transmembrane, cytoplasmic and/or membrane associated.   On the cellular 
level TK activation typically promotes growth, differentiation and proliferation.  Specific TK 
driven processes include immune cell activation, vasculogenesis, tissue/growth and repair, 
homeostatic signaling and transmission of mechanical stresses from the cytoskeleton to the 
cellular signaling machinery, among many others (6–10). TK signaling is also arguably the most 
important driver of cellular transformation and tumor growth, with most tumors displaying excess 
TK activation or activation of a TK driven pathway(11–14).  In fact, the non-receptor tyrosine 
kinase, v-SRC was the first oncogene discovered and shortly thereafter v-SRC activity was 
linked to tyrosine phosphorylation by studies which connected SRC expression with tyrosine 
phosphorylation in polyoma virus infected cells and polyoma virus middle-T protein tyrosine 
phosphorylation (15, 16).    
Tyrosine kinases function by catalyzing transfer of the -phosphate (-PO3) of ATP to the 
hydroxyl group on the amino acid tyrosine (17).  Generally, TKs display relatively low basal 
activity when compared to their activated state which is induced by two major mechanisms, 
activation loop phosphorylation and in the case of RTKs, ligand binding (3, 18–20).  Most TKs 
contain a short unstructured loop within their kinase domain containing one or more tyrosines.  
Phosphorylation of these tyrosine residues induces structural changes within the kinase domain 
that allow for substrate binding and phosphorylation.  RTK activation and signaling requires a 
second layer of regulation induced by the binding of a small protein ligand (also known as a 
mitogen or growth factor) to the extracellular domain.  Ligand binding promotes allosteric 
changes in the ligand binding domain of the protein which promote receptor dimerization.  
Dimerization then significantly increases the chance activation loop phosphorylation.  
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Dimerized, activated RTKs then transphosphorylate substrate tyrosines on their binding 
partners.  In either case, phosphorylated sites serve as docking sites for downstream signaling 
proteins, which are themselves often phosphorylated (see below).  Isolated RTKs generally 
display only moderate substrate specificity, defined by the amino acid sequence surrounding the 
substrate tyrosine (21). Additional binding domains within the kinases provide further specificity 
by facilitating kinase-substrate interactions and subcellular localization (22). 
 
Protein Tyrosine Phosphatases 
The activity of tyrosine kinases is opposed by the action of protein tyrosine phosphatases 
(PTPs).  PTPs are a diverse and rather understudied family of proteins which include both 
classical tyrosine specific phosphatases and dual specificity phosphates capable of 
dephosphorylating phosphotyrosine, phosphoserine and phosphothreonine residues. Classical 
PTPs which include 38 cytoplasmic and membrane-associated members, have been implicated 
as the major negative regulators of tyrosine phosphorylation. For the purposes of this work the 
acronym “PTP” will refer only to the classical, tyrosine specific PTPs (23, 24).    
All PTP family members contain the highly conserved active site motif [I/V]HCSXGXGR[S/T]G, 
which is essential for their function.  A major mechanism of PTP regulation is the reversible 
oxidation of the active site cysteine.  When oxidized, the cysteine thiolate group is converted to 
sulfenic acid (SOH), sulfenylamide (-SN) or forms of intramolecular disulfide bonds.  All of these 
modifications prevent the sulfur atom on the cysteine from functioning as a nucleophile in the 
dephosphorylation reaction.  Irreversible inhibition of PTPs by further oxidation to sulfinic (SO2H) 
or sulfonic (SO3H) acid can also occur within the cell (25, 26).  It should also be noted that 
serine, threonine, and tyrosine phosphorylation have also been described as mechanisms for 
controlling the activity of PTPs (27, 28).   
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Like TKs, PTPs are thought to display only moderate to low specificity.  Studies with substrate 
trapping mutants, inactivated PTP domains isolated from their parent proteins  and used as 
probes for their interaction partners, support this assertion (29, 30).  However, more recent data 
mass spectrometry (MS) approaches using PTP knockdowns suggest that some PTPs can 
function as highly specific positive and negative kinase mediated pathways (31). Nevertheless, 
data for PTP specificity is limited, and specific substrate motifs have been difficult to pin down.       
  
Src-Homology-2 and Phosphotyrosine Binding Domains 
Originally identified as sequences homologous to a region of the v-SRC oncogene, SH2 
domains are small modular phosphotyrosine binding domains, approximately 100 amino acids 
in length (32).    In total 120 SH2 domains have been identified in 110 proteins, many of which 
are involved in oncogenic signaling (33, 34). The binding affinities of SH2 domains are defined 
by specific amino acid motifs sequences up and downstream from the phosphorylated tyrosine 
residue, specifically, amino acids at positions -1 through +4 ( -1:pY: +1:+2:+3:+4) (35, 36). 
Binding motifs for specific SH2 domains can loosely be divided into four categories, pYE/D, 
pYXN, pXXM and pYXXP/L (X= any amino acid) (36) (Table i 1).  However, there is significant 
overlap between these groups and the amino acid sequence surrounding these motifs can 
greatly influence SH2 affinity (37).  It is also worth noting that many SH2s appear to display 
more complex binding affinities which cannot be defined by a specific motif. Also, a significant 
portion of these domains (~30) have not been studied, as they are either poorly soluble or are 
non-functional (unable to recognize phosphotyrosine controls) as recombinant proteins (36, 38).   
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SH2 Domains  Motif  
GRB2, GRB7, GRAP, GADS  pY-X-N  
CRK, CRK-L, NCK1, NCK2, 
SHP1, SYK, SH2B, RASA1  pY-X-X-P/L/V  
SLP76, MIST, FER, FES, ITK, 
GRB14, BRK  pY-D/E  
PI3K1, PI3K3  pY-M-X-M  
STAT, JAK, SOCS, RIN 
Families  
Poorly Defined*  
 
Table i 1. SH2 Binding Specificities. Table of SH2 domain binding specificities, with SH2 
domain containing proteins on the left and binding motif on the right.  The table grossly 
oversimplifies SH2 binding specificities, but is a useful starting place from which to start 
examining SH2-pY binding.   The exact binding motifs of each SH2 domain are significantly 
more nuanced, with specific combinations of amino acids effecting binding in a both a positive 
and negative manner (37).  As a result, defining an exact consensus motif for any one SH2 
domain is extremely challenging.  
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 SH2 domains are present in proteins with a wide variety of functions including: almost all 
cytoplasmic tyrosine kinases (e.g. SRC, ABL-Abelson Tyrosine Kinase, JAK-Janus Kinase and 
BTK-Bruton’s Tyrosine Kinase families, among others), the PI3K (Phosphoinositoyl-3-kinase) 
family of lipid kinases, the SHIP family of lipid phosphatases, the SHP family of tyrosine 
phosphatases, the CBL family of ubiquitin ligases and a large number of adaptor proteins which 
connect tyrosine phosphorylation events with cellular signaling pathways, particularly through 
small GTPases (e.g. GRB2, GRB7 and GRAB with RAS, RIN family proteins with RAB7 and 
CRK family proteins with RAS/RAC1/RAP1) (34, 39). For each of these protein types, SH2 
domains function to localize enzyme activity to the site of their specific pY binding sites, often 
located within pY-signaling hubs such at RTKs and focal adhesion proteins.  Many SH2 domain 
containing proteins also contain other modular binding domains such as phospholipid binding 
PH (Plekstrin Homology) and poly-proline binding SH3 (SRC-Homology 3) domains that further 
promote cellular localization, substrate recruitment and protein complex formation. Most SH2-
domain containing proteins function within the cytoplasm where the bulk of tyrosine 
phosphorylated proteins reside.  However a small number of SH2 domain containing proteins 
have been shown to function in the nucleus.  For instance, the STAT family of proteins are 
translocated into the nucleus following phosphorylation and dimerization where they function as 
transcription factors (40). Likewise the SRC family kinase LYN has been shown to localize to 
the nucleus where it functions as in the DNA damage response and as a regulator of the cell 
cycle (41).   
 
Quantifying Phosphotyrosine Dynamics: Isolating TK and PTP activity in vivo 
Tyrosine phosphorylation is a highly dynamic process, with a continuous flux of 
phosphotyrosines passing through any pY signaling pathway (18).  This flux, defined by 
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phosphorylation and desphosphorylation rates, when these two forces are at equilibrium these 
rates are the same and the absolute level of phosphorylation is constant (18, 42).  Quantification 
of these processes requires isolation of each process. This can be done in vitro using purified 
proteins and substrates, or in vivo using targeted inhibitors.  A number of in vitro assays have 
been performed to quantify reaction and binding constants for kinases, phosphatases and 
SH2s.  In vitro kinase and phosphatase activity assays typically require immunoprecipitated or 
recombinant proteins, and as a result do not take into account cellular factors which influence 
activity (42–45).   
TK Activity 
In vivo kinase activity likely depends on a number of factors including, kinase expression, spatial 
organization, activation loop phosphorylation, substrate concentration and the presence of 
kinase allosteric activators or inhibitors (46–49).  Defining each of these factors can be difficult. 
PTP inhibition by active site oxidation has been exploited in multiple studies to measure TK 
activity in vivo. This method typically utilizes the irreversible phosphatase inhibitor pervanadate 
(PV), a peroxide of sodium orthovanadate, a phosphate-like competitive reversible inhibitor of 
PTP activity that is thought to be more specific for PTPs than peroxide treatment alone.  PV is 
used to isolate kinase activity for in vitro and in vivo assays of tyrosine kinase activity (44, 50).  
When live cells are treated with this reagent, cellular phosphorylation continues to rise at a rate 
defined by solely by the kinase activity, which can be quantified using phosphospecific 
antibodies.  This method has been exploited in the work presented in this dissertation, and is 
further examined in Chapters 3 and 4.  
PTP Activity 
Assessment of in vivo phosphatase activity is equally complicated.  Oxidation, expression and 
localization all affect PTP activity (27, 51, 52).  Our limited understanding of PTP specificity 
further complicates the application of in vitro PTP activity measurements to in vivo system.  To 
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overcome these issues, in vivo protein specific dephosphorylation rates can be measured by 
exploiting tyrosine kinase inhibitors (TKIs). By blocking the action of kinases, TKIs allow for 
quantification of the protein dephosphorylation without directly knowing which PTPs are 
mediating the effect (42).  This method is useful when studying substrates for which the kinase 
responsible is well defined.  Due to the important role they play in tumor growth, a number of 
cell permeable tyrosine kinase inhibitors have been developed over the past 20 years (13).  
Global tyrosine kinase activity can also be suppressed using the phytoestrogen Genestein.  
However, specific TKIs are preferred as this molecule has multiple non-TK effects on cellular 
physiology (53, 54).   
 
Epidermal Growth Factor Receptor Activation and Signaling 
In 1986 Stanley Cohen was awarded the Nobel Prize for the discovery of EGFR and its ligand 
EGF (Epidermal Growth Factor) (55, 56). Since the time of Cohen’s seminal work EGFR has 
become one of, if not the most studied TK.  The receptor belongs to the ErbB (erythroblastoma) 
family of RTKs, which includes ErbB1/EGFR, ErbB2/Her2, ErbB3 and Erb4. The intracellular 
domains all family members share sequence homology with the viral ErbB oncoprotein, a 
mutant form of the chicken EGFR homolog found in avian erythroblastosis virus (57). EGFR, 
Her2 and to a much lesser extent ErbB3,4 are known to function as oncogenes, with EGFR 
playing a role in nearly 30% of all andenocarcinomas.  Cellular signaling proteins activated 
downstream of these receptors, including KRAS, BRAF, PI3K, and STAT family proteins, are 
also key drivers in the growth of many tumor types (58).  
Upon binding of EGF, EGFR monomers undergo a conformational change that allows for 
homodimerization or heterodimerization with other members of the ErbB family (48).  Receptor 
dimerization brings the cytoplasmic domains to interact (59, 60).  However, unlike most TKs, 
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EGFR kinase activity is not dependent on phosphorylation of a kinase domain activation loop 
(61). Instead the kinase domains of each EGFR are thought form an asymmetric dimer in which 
the C-terminal lobe of one receptor binds to and the activates the kinase domain of its partner in 
a manner resembling cyclin mediated activation of Cyclin Dependent Kinases (59).  
Following activation, dimerized receptors autophosphorylate one another. The cytoplasmic tail 
of EGFR contains at least nine unique tyrosine phosphorylation motifs which have been shown 
to serve as docking sites for SH2 and PTB (phosphotyrosine binding) domain containing 
proteins(58, 62).  While a number of SH2 containing proteins have been implicated as 
phosphotyrosine specific EGFR binding proteins, five, including GRB2, PLC1, SHC1, SHP2 
and CBL, have been thoroughly vetted in the literature (43, 58) (Figure i 2). Each of these 
proteins promotes the activation of multiple downstream pathways including the 
RAS/RAF/MEK/ERK, PI3K/AKT, DAG/PKC and clathrin mediated receptor endocytosis and 
recycling. EGFR activation in is also known to induce disassembly of focal adhesions, leading to 
dephosphorylation of their constituent proteins, including the p130-CRK Associated Substrate 
(p130CAS), and a reduction in signaling through CRK family SH2 domain containing proteins 
(63–66).   
EGFR hyperactivation as a result of kinase domain mutation and overexpression is a powerful 
mechanism for cellular transformation (66).  EGFR mutations are a major driver of 30-60% of all 
non-small cell lung cancers, the leading cause of cancer death in the US (66–68).  EGFR 
signaling has also been shown to be important in ERBB2 overexpressing breast cancers and in 
a large percentage of colorectal cancers (69, 70).  In these tumors there is constitutive 
activation of the mitogenic EGFR-dependent pathways listed above.  As a result, a number of 
anti-EGFR agents have been developed for clinical use.  Cetuximab, a chimeric (mouse/human) 
monoclonal antibody has been developed for use in colon cancers.  This antibody prevents  
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Figure i.2. Epidermal Growth Factor Receptor Phosphotyrosine Sites and Downstream 
Signaling. EGFR contains nine well studied tyrosines which are known to be phosphorylated 
and function as SH2-binding sites.  The phosphosites are listed on the left and are placed in 
their approximate position along a linear model of the receptor. Specific motifs are listed to the 
right of enzyme, with phosphorylated tyrosines in lower case. The most well established SH2 
domain containing proteins for each site are listed.  These SH2 proteins represent a literature 
consensus and are not the only possible protein partners. Pathways activated by each protein 
are listed on the far right.  
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receptor activation and leads to receptor down regulation, but is only effective in cancers in 
which the EGFR downstream protein, KRAS has not been mutationally activated.  ATP-
analogues are another class of well studied EGFR inhibitors used both clinically and 
experimentally (see above).  These include Erlotinib and Gefitinib which are used mainly in the 
treatment of NSCLCs with EGFR activating mutations.  While both these classes of inhibitors 
prolong survival, resistance develops almost universally, either via activation of proteins 
downstream from EGFR or as a result of so-called “Gate Keeper” mutations in the receptor 
which allow for ATP hydrolysis and tyrosine phosphorylation but prevent the inhibitor from 
accessing the kinase active site (71, 72).       
 
KRAS Activation and Signaling 
Nex to EGFR, the small GTPase RAS is one of the most clinically important pro-oncogenes 
gene families. This family includes K-, R- and N-RAS.  RAS activation occurs following 
recruitment of SH2 domain containing proteins such as SHC1 and GRB2 to the phosphorylated 
proteins including EGFR.  Together these proteins recruit the RAS activator SOS (Son of 
Sevenless) to the site of phosphorylation. SOS functions as a guanine nucleotide exchange 
which promotes the release of GDP from the RAS allowing it to bind GTP.  GTP-binding 
activates RAS allowing it to bind and activate proteins futher downstream (73). In RAS driven 
tumors, RAS is typically activated as a result of missense mutations in either codon 12 or 13 
(the common mutant KRASV12 being used in our proposed work) which prevents conversion to 
the inactive form of RAS.  Activated RAS is known to binding to and activate a number proteins 
including RAF. RAF in turn actives the pro-proliferative mitogen-activated protein kinase 
pathway (MAPK pathway) and the PI3K pathway which promotes anti-apoptotic AKT pathway 
signaling (14, 74).   
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Methodologies Overview: 
Quantitative Mass Spectrometry 
A complete understanding and analysis of phosphotyrosine dynamics and phosphoprotein-SH2 
interactions requires at least some knowledge of the phosphosite sequences within a specific 
biological sample (tumor lysate, cell type, treatment condition).  Currently phosphospecific mass 
spectrometry studies have identified over 40,000 non-redundant phosphotyrosine sites (62).  
However, to truly incorporate this data into dynamic models of cellular signaling we must have 
some measure of the abundance of specific phosphosites across multiple time points and/or 
experimental conditions.    
Over the past few decades two major isotope-based tagging methods have been developed to 
tackle this issue; SILAC (Stable Isotope Labeling of Amino Acids in Cell Culture) and iTRAQ 
(Isobaric Tagging for Relative and Absolute Quantification).  SILAC relies on the incorporation of 
a particular amino acid containing some variation of heavy or light isotopes (e.g. C12 and C13) 
into cell cultures assigned to different experimental conditions. Cells are combined, lysed and 
protease treated before MS analysis.  In contrast, for iTRAQ (the method used in the studies 
presented in here) cells are lysed and protease treated first. Then phosphopeptides from each 
experimental treatment are isolated, covalently tagged with equivalent molecular weight tags, 
combined, separated by mass to charge ratio by an initial round of mass spectrometry and 
fragmented by ionization. Fragmentation causes the cleavage of the molecular weight tags in 
such a way that each experimental tag has a unique molecular weight.  The peptide fragments 
are then analyzed again by mass spectrometry allowing for peptide sequence identification. The 
relative abundance of each individual phosphopeptide is determined by the relative amount of 
each tagged identified (Figure i.3).   While both methods have their merits the major advantage 
of iTRAQ is that it can be applied to both cell cultures and isolated tissues.   
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In recent years, quantitative phospho-mass spectrometry has provided significant information 
about phosphotyrosine signaling networks, including that of EGFR.  Temporal analyses of 
phosphotyrosine changes, as well as those in phosphoserine and phosphothreonine, have been 
used to reconstruct phosphorylation dependent signaling pathways and link temporal changes 
in phosphorylation at specific sites with changes in signaling output over time (75).  MS has also 
been combined protein-protein interaction data obtained from SH2-domain based binding 
assays, SH2-pY interaction tools and protein interaction databases, such as those listed below, 
to reconstruct complex TK driven cellular signaling networks (76, 77).      
 
The Domainomics Approach: Domainomics, Global profiling of in vivo SH2-pY interactions 
and Single Molecule Imaging of SH2-Phosphotyrosine Interactions.   
Domainomics 
Many proteins contain independently folding globular domains capable of binding short peptide 
motifs even when both domain and motif are removed from the context of their full-length 
protein (78, 79). Modular protein interacting domains facilitate protein-protein interactions 
required for a diverse set of cellular processes including signal transduction and subcellular 
localization. Domains are categorized based on structural and sequence homology, with each 
domain family recognizing motifs with similar characteristics, such as phosphorylated tyrosine 
(pTyr) or proline rich sequences. The combination of modular domains within a protein 
contributes to its biological function by defining its protein interaction network. Post-translational 
modification (PTM) of amino acid side chains within specific peptide motifs can modulate 
domain-motif binding. And it is the variation of in domain specificity and motif modification that is  
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Figure i.3. Schematic of iTRAQ mass spectrometry. Isobaric tagging for relative and absolute 
quantification (iTRAQ) allows for comparison of the relative abundance of specific phospho-sites 
across multiple experimental samples.  Cells from each experimental point are lysed, proteins 
are cleaved using trypsin and covalently labeled using an isobaric tags containing a reporter 
and balance.  Balance and reporter used for different time points contain varying amounts of 
heavy and light isotopes, with each complete tag having the same molecular mass (therefore 
isobaric), but each reporter having a different mass.  The peptides are then combined, and 
enriched for phosphorylation sites using TiO2 and anti phosphotyrosine antibody columns.  
Peptides are then run through tandem MS, often using a triple quadrapole setup. Peptides are 
separated by mass and ionized which includes balance-reporter cleavage. Protein and reporter 
ions are separated again by MS.  The molecular weight and specific pattern of peptide ions is 
used to determine peptide sequence. The relative abundance of each of the much lighter (lower 
mass to charge, m/z, ratio) reporter ions equates the relative abundance of that peptide in each 
experimental sample.      
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the basis for much of the elegant and complicated protein signaling networks required for life 
(80). Over the past decade, exploitation of a number of high-throughput proteomic technologies 
has led to the dissection of vast protein interaction networks and helped to decode the role of 
PTMs in altering network topology(81).  
A significant portion of proteomics and signaling systems biology studies have taken advantage 
of modular domains as a means to assess protein-protein interactions. We refer to this modular 
domain-based proteomics as “domainomics” (32).  While this may be a somewhat artificial 
segmentation, it is meant to draw attention to the potential of domains and their motifs as tools 
in contemporary proteomics. The work presented here focuses on SH2-domain based 
domainomics approaches. 
 Independent folding of SH2 domains, which preserves binding capabilities, allows for their use 
as affinity and detection reagents in a manner similar to that of phospho-specific antibodies. 
Unlike antibodies, SH2 domains naturally have wide-ranging specificity (see above). However, 
promiscuity in ligand selection is a physiological propensity rather than experimental noise, as it 
would be for antibodies.  Interpretation of SH2 binding data is therefore more complex, requiring 
information about SH2-domain containing protein expression levels, phosphosite availability, 
and SH2-pY affinities and specificities. 
Multiple technologies have been developed to assess SH2-pY interaction using the 
domainomics approach including: support dependent forward phase and reverse phase assays, 
in-solution assays and in vivo binding assays (figure i.4).  In forward phase arrays, domains are 
immobilized on a solid support and probed with a tagged phosphopeptides or protein.  
Pioneered by Espejo et al 2002 and improved for uses with SH2 domains by the Macbeath 
group, this methodology has been used to define SH2-pY motif specificity and affinity (43, 82). 
However, a major concern for the forward phase format is whether immobilization of  
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Figure i.4. Domainomic approaches to quantifying SH2-pY interaction. A number of domain-
based approaches have been developed to identify and quantify SH2-pY interactions. Forward 
phase arrays utilize arrays of SH2 domains and can be useful for identifying the binding 
partners of a specific, usually small set of proteins.  Reverse phase assays are useful for 
screening large peptide libraries for their ability to bind specific SH2 domains.  In-solution 
assays remove the effect of non-specific substrate (e.g. nitrocellulose membrane) binding.  
These methods include: fluorescence polarization, proximity ligation and Förster Resonance 
Energy Transfer (FRET) which can also be used in vivo.  A number of other in vivo SH2 domain 
based interaction assays have also been developed or are in development including light 
inducible pY-SH2 covalent bonding and BioID.  
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recombinant protein domains might disrupt the conformation and orientation required for ligand 
binding (83, 84). The method also hampers high throughput screening as a unique SH2 domain 
array is required for every phosphopeptide tested.  
 In reverse phase arrays, cell lysates containing phosphorylated lysates or phosphorylated 
synthetic peptides are immobilized and probed with SH2 domains.  This method is particularly 
suitable to screen large-scale libraries of peptide motifs to determine consensus sequences for 
domains, as thousands of phosphorylated peptides or even whole cell lysates can be probed 
with a single SH2 domain at once(38). Reverse phase assays have also have been extensively 
utilized in the Mayer Lab in the form of far-Western/SH2 profiling (see below) and by a recent 
large scale study of SH2 specificity that used recombinant SH2 domains to probe microarray of 
thousands of tyrosine phosphorylated peptides  (36, 67).   
For in-solution methods, both SH2 domains and phosphosite are solubilized, which minimizes 
membrane associated binding artifacts seen in reverse and forward phase assays. In-solution 
assays include; FRET (Fluorescence Resonance Energy Transfer), fluorescence polarization 
(FP) and proximity ligation-based assays (PLA). FRET dependent methods measure the 
transfer of energy from excited electrons between nearby fluorophores on SH2-containing 
proteins and their phosphorylated targets. Unlike most other in-solution methods, they typically 
directly measure interactions and therefore can used for recombinant proteins, cell lysates and 
in vivo (85–88). However, these assays can have low sensitivity due to low signal to noise. FP-
based assays assess the rotation of fluorescently tagged peptides bound to recombinant SH2 
domains and are particularly useful for defining binding constant (Kd) values, though they too 
have issues with signal to noise ratios (89). Proximity ligation assays attempt to overcome low 
signal to noise issues using amplification. These assays use SH2 domain and protein specific 
probes tagged with oligonucleotides which are ligated when in close proximity and serve as 
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templates for PCR or rolling circle based amplification which is quantified using real-time PCR 
(50).   
It is worth noting that all of the aforementioned assays require that proteins be removed from 
their native intracellular localization.  Over the past few years in vivo binding assays have been 
developed, capable of detecting SH2-pY interactions occurring in live cells. These methods are 
typically significantly lower throughput than those mentioned above and include photo-
crosslinking and BioID, as well as the phosphatase protection assay and super resolution 
imaging based methods that are discussed in Chapters 2 and 3, respectively. Photo-
crosslinking methods utilize exogenous t-RNAs to incorporate synthetic amino acids into SH2 
domains.  The amino acids form covalent crosslinks with nearby proteins upon exposure to light 
of specific wavelength, allowing the experimenter to essentially freeze in vivo SH2-pY 
interactions in time, which can then be identified by MS after cell lysis (90).  BioID utilizes 
proteins tagged with the bacterial biotin ligase (BirA) which biotinylate proteins within close 
proximity, which are then analyzed by Western or MS after cell lysis (91). This method is 
currently under investigation for analyzing SH2-pY interactions.  Phosphatase protection assays 
utilize SH2 mediated protection to identify pY-SH2 interactions in vivo and will be discussed 
further in Chapter 3. Super resolution imaging can be used to monitor and quantify the 
movement and localization of individual ectopically expressed fluorescently tagged SH2 domain 
containing proteins in live cells.  One such method, single particle tracking photo-activated light 
microscopy (sptPALM), is described in detail below and utilized in Chapter 2.  
Profiling the global phosphoproteome using SH2 domains 
To develop an unsupervised method for identifying SH2 domain binding sites and quantifying 
their dynamics, our laboratory has developed SH2 profiling (38).  SH2 profiling utilizes far-
Western blotting, in which non-antibody proteins are used as affinity reagents for proteins or 
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post-translational modifications of interest (92). In SH2 profiling recombinant SH2 domains are 
used as probes for phosphotyrosine sites within cells lysates which are either spotted onto 
membranes or run on PAGE (polyacrylamide gel electrophoresis) gels and transferred on 
nitrocellulose membranes. Binding of each SH2 domain is then detected using a non-specific 
high affinity probe conjugated with a detection agent (e.g. SH2-GST and anti-GST-HRP) and 
quantified using chemiluminesnce or fluorescence. In the case of lysates run on PAGE, signal 
quantification can be further divided by protein band or molecular weight. Clustering methods 
can then be applied to the data in order to detect significant subsets of lysates, SH2 domains, or 
phosphoproteins (Figure 1.5).  Multiple experiments performed in the Mayer lab, as well as 
others, have shown that this method is capable of recapitulating much of the SH2-
phosphotyrosine binding observed by more time consuming, lower throughput methods such as 
mutational analysis and immunoprecipiation (12). By quantifying and comparing the binding 
patterns and kinetics from multiple SH2 domain probes one can reconstruct the SH2 domain-
phosphosite interaction landscape occurring within in the cell.   SH2 profiling been shown to be 
useful tool for clustering cells and tumor tissues by functional characteristics such drug 
sensitivity and is currently under investigation for use as a prognostic marker (12, 50, 67).  The 
method is also well suited for analysis of SH2 binding site kinetics, as it allows for the 
quantification and comparison SH2 binding across multiple phosphoproteins and time points 
(See Chapter 2).   
In vivo single SH2 domain imaging 
One drawback of SH2 profiling based analyses is that like other post-lysis interaction assays, 
the spatial orientation of phosphoproteins is lost prior to interaction profiling.  In situ methods for 
identifying SH2–phosphoprotein interactions such as antibody-based immunofluoresence using 
fixed cells can provide some insight, but can be difficult to control across multiple time points 
and can be associated with a number of method dependent artifacts.  
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Figure i.5. SH2 Profiling.  SH2 profiling is a reverse phase assay which uses SH2 domains as 
affinity reagents to assess the global phosphorylation state of lysates from different cell lines or 
experimental conditions. Cells from different experimental points are lysed, separated by gel 
electrophoresis, transferred to nitrocellulose membranes and probed with the large set of 
recombinant SH2 or PTB domain probes. Probe binding is detected using HRP- or fluorophore-
tagged secondary antibodies by digital scanners, quantified and compared using hierarchical 
clustering.   
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To develop a method to monitor SH2 binding across both space and time in live cells we have 
collaborated with the Ji Yu laboratory, and specifically Dr. Dongmyung Oh, to develop a method 
for tracking single SH2 molecules as they are recruited to the surface of cells treated following 
RTK activation. The method incorporates and builds on a sptPALM method developed and used 
by Manley et al. to monitor tracking viral Gag and Vesicular Stomatitis Virus – G proteins on the 
plasma membrane of living cells (93) (Figure i.6).  The protocol uses exogenously expressed 
photo-convertible fluorescently tagged SH2 domains to monitor EGF stimulated SH2 domain 
recruitment to the basal membrane of adherent cells on a glass slide. Total internal reflection 
(TIR) optics are used to excite only molecules at or near the plasma membrane (Z-axis 
resolution =  200nm) (94). To follow individual molecules, UV light is used to convert the 
excitation and emission spectrums (ex:506nm/em:561nm to ex:571nm/em:581nm) of a fraction 
of exogenously expressed SH2 domains tagged with the phophoactivatable fluorophore tdEOS, 
a fluorescent protein originally derived from the stony coral Lobophyllia hemprichii (95, 96).  
Individual molecules can then be localized by fitting their point-spread functions to a Gaussian 
distribution, allowing for lateral resolution of approximately 30nm. The individual SH2 domains 
are then tracked by acquiring TIR images using short exposures and a rapid frame rate over a 
set period of time. This method provides a powerful tool for monitoring changes in the spatial 
orientation and mobility of individual SH2 molecules on the plasma membrane (93, 97). Using 
this method we have developed an SH2 membrane hopping model in which SH2 domain 
interaction with the plasma membrane is sustained by multiple rebindings prior to returning to 
the cytosol (94) (Figure i.7).  One major issue with the method is that it does not allow the user 
to easily identify the specific membrane phosphoprotein or set of proteins that each SH2 domain 
is binding.  As a result, single molecule and TIR experiments must with combined with more  
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Figure i.6. Total Internal Fluorescence Microscopy and Single Particle Tracking Photoactivated 
Light Microscopy.  An excitation beam focused at a cell membrane-glass slide interface at an 
angle sufficient to produce total reflection will produce an evanescent field along the interface 
with the same wavelength.  This field extends into the cell with a depth of approximately 1/3 the 
wavelength of the excitation beam. This results in an excitation field extending about 200-300 
nm into the cell and allows users to visualize only those fluorescently tagged molecules within 
that region in real time. This can be used to measure the recruitment of SH2 domains to 
phosphorylated membrane proteins in response to growth factor stimulation.  The resolution of 
specific molecules on the surface can be greatly improved by using a photactivatable 
fluorophore, such as tdEOS.  When exposed to higher energy blue or UV light, a small fraction 
of tdEOS molecules are “activated”, causing them to fluoresce at different excitation/emission 
spectrums.  This allows users to track a small number of molecules as they are recruited to, and 
diffuse across or away from the excitation field.  This method can be used to determine 
membrane on-rates, off-rates, diffusion constants and diffusion constraints.  
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traditional biochemical analyses, including Western, FW and MS, which can provide more 
information about SH2 domain binding partner phosphorylation dynamics.   
 
Computational Modeling and EGFR Signaling 
The mechanism by which dynamic or complex cellular processes function or produce a specific 
output are often difficult to determine or experimentally test using traditional biochemical and 
imaging methods.   In these cases, computational reaction modeling can be a useful tool.  In 
computational modeling interactions between biological species or components, such as 
structural proteins, enzymes, RNA, DNA etc., are represented by a set of interdependent 
reaction rates, which in turn are a function of component rate or binding constants and 
concentrations.  By varying species parameters within this system of interconnected equations 
one can gain insight in those inputs that have the greatest effect on the output in question.  The 
resulting hypothesis can then be tested by further wet lab experimentation. Data from these 
experiments can then be used to further refine the model.  
Parameters which are not known can be approximated by determining which values allow the 
model to most closely recapitulate experimental results. However, in using a model containing 
too many approximated values one runs the risk of receiving erroneous results (98).  The 
accuracy of computational models depends largely on the accuracy of the inputs and their 
relationship to one another.  A significant effort has been made over the past twenty-five years 
to quantify EGFR-EGF and SH2 domain-pY EGFR interaction affinities and specificities (21, 35, 
43, 89, 99, 100). As a result, SH2 domain containing protein mediated EGFR signaling has 
been modeled by multiple groups in order to gain insight in the process. Many of these utilize 
complex modeling methods which are beyond the scope of the work presented here (44, 49, 
101, 102).  However, only a few of these models utilize experimentally determined values for  
26 
 
 
Figure i.7. Rebinding model of SH2-pY EGFR interaction. Phosphosite clustering increases the 
probability that an SH2 bound at the membrane will rebind a nearby membrane-associated 
phosphosite before exiting into the cytosol.  As a result, SH2 domain containing proteins dwell 
at the membrane for a much greater time than would be expected from in vitro measured off-
rates.  
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EGFR phosphorylation and dephosphorylation or SH2 protein concentrations. As a result, they 
are more susceptible to the parameter fitting hazard described above. 
Traditional biologists and biochemists often do not have the necessary training or mathematical 
background to create a mathematical model from scratch based on their own data (103–105).  
To rectify this issue, the Center for Cell Analysis and Modeling at UConn developed the Virtual 
Cell (VCell), a modeling software with a reasonably friendly user interface whose base functions 
can be utilized with minimal training (106).  In the work presented here, the VCell software is 
exploited to model our findings using experimentally determined parameters in an attempt to 
validate a proposed explanation for experimental findings. 
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Abstract 
While the affinities and specificities of SH2 domain-phosphotyrosine interactions have been well 
characterized, the spatio-temporal changes in phosphosite availability in response to signals, 
and their affect on recruitment of SH2-containing proteins in vivo, are not well understood. To 
address this issue, we used three complementary experimental approaches to monitor 
phosphorylation and SH2 binding in A431 cells: 1) phospho-specific mass spectrometry; 2) far-
Western blotting; and 3) live cell single-molecule imaging of SH2 membrane recruitment. Far-
Western and MS analyses of EGF-stimulated cells identified both well-established and 
previously undocumented EGF-dependent tyrosine phosphorylation and binding events, as well 
as dynamic changes in binding patterns over time. In comparing SH2 binding site 
phosphorylation with SH2 domain membrane recruitment in living cells, we found in vivo binding 
to be much slower. Delayed in vivo SH2 domain recruitment correlated with clustering of SH2 
domain binding sites on the membrane, consistent with membrane retention via SH2 rebinding. 
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Introduction 
Receptor tyrosine kinases (RTK) and tyrosine kinase-associated receptors play an essential 
role in transducing extracellular signals into the cell. These proteins function as central signaling 
nodes for a diverse set of normal biological processes including proliferation, differentiation, 
immune cell activation, neuronal development, angiogenesis, and cell migration. Dysregulated 
tyrosine kinase activity is also a primary driver of human cancer. Upon activation, RTKs 
phosphorylate tyrosine residues on themselves and associated proteins, which then serve as 
binding sites for Src homology 2 (SH2) and phosphotyrosine binding (PTB) domains found 
within downstream signaling proteins (3, 107, 108).  
120 SH2 domains have been identified in 110 different proteins (33, 36). The central role these 
proteins play in cellular signaling has made them popular targets for study. The affinities and 
specificities of many phosphotyrosine (pY)-SH2 interactions have been quantified, and much of 
the complex web of downstream pathways initiated by SH2 domain binding has been unraveled 
(36, 43, 89, 109, 110). By contrast, much less is known about the role that spatial and temporal 
changes in protein phosphorylation play in signal transduction. Current experimental 
approaches, however, have the potential to address system dynamics directly. 
Methods such as quantitative mass spectrometry (MS) and live cell fluorescence microscopy 
are now are capable of tracking temporal changes in cellular physiology across remarkably 
short time steps. For instance, isotopic protein-tagging MS methods, including SILAC and 
iTRAQ, allow us to quantify the relative and absolute abundance of pY sites found within 
hundreds of proteins across multiple time points (111, 112). Data from these experiments has 
been used to map temporal changes in molecular signaling, providing us with a more 
comprehensive understanding of pathway dynamics (75, 112). At the same time, high resolution 
microscopy, coupled with more traditional imaging methods and biochemical studies, has 
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allowed us to begin to dissect the spatial reorganization of RTKs and their effectors following 
receptor activation (49, 60, 113–118).  
We previously used single particle tracking photoactivated localization microscopy (sptPALM) 
(93) to visualize and quantify individual SH2 domain binding events at the plasma membrane in 
response to receptor activation (Oh et al., 2012). From these studies we developed a model in 
which the high density of tyrosine-phosphorylated sites on the membrane results in the repeated 
rebinding of SH2 domain-containing proteins before they can escape into the cytosol. This local 
rebinding suppresses the apparent off-rate and prolongs the membrane dwell time of SH2 
domain-containing proteins. Furthermore, we showed that clustering of SH2 binding sites, a 
well-known consequence of RTK activation (60, 115, 119, 120), further suppressed the 
apparent off-rate of the GRB2 SH2 domain, suggesting that signal output could be influenced by 
changes in physical properties such as phosphosite distribution. 
Traditional two-dimensional signaling diagrams and phosphopeptide-based affinity studies fail to 
fully capture the complexities and importance of spatial and temporal changes in receptor 
activation, protein phosphorylation, and SH2 domain-containing protein recruitment. Indeed, 
existing biochemical and proteomic methods each have strengths and technical limitations, such 
that no single approach provides a clear and unambiguous perspective. Thus to better 
understand RTK signaling dynamics, we have employed three orthogonal experimental 
techniques: SH2 domain-based reverse-phase binding assay (far-Western blotting) to assess 
global changes in SH2 binding sites, iTRAQ (isobaric tagging for relative and absolute 
quantification)-based phosphotyrosine-specific MS to identify changes in the abundance of 
specific phosphopeptides, and live cell single particle tracking using total internal reflection 
fluorescence (TIRF) microscopy to assay recruitment of SH2 domains to the membrane in vivo 
(Figure 1.1). Combining these complementary approaches to analyze the EGF response in the 
same experimental system revealed previously uncharacterized properties of the EGFR   
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Figure 1.1.  Outline of multimodal experimental approach to analysis of EGFR phosphorylation 
and SH2 binding in A431 cells.  FW blotting provides a link between the phosphorylation level 
changes quantified by MS and the in vivo SH2 binding measurements made using TIR imaging.   
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signaling network. We quantified and compared binding site creation kinetics for a large set of 
SH2 domains with high temporal resolution, and were able to define a previously unappreciated 
role for phosphosite clustering in sculpting the dynamic profile of signal output downstream of 
tyrosine kinase activation. 
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Results 
Dynamic EGF-dependent changes in tyrosine phosphorylation  
We first performed far-Western blotting, a reverse-phase SH2 binding assay (38) to quantify 
changes in binding sites for multiple SH2 domains across the set of phosphoproteins in EGF-
stimulated A431 cells, an EGFR-overexpressing squamous-cell carcinoma cell line (121, 122). 
Cells were starved overnight, stimulated with 25 ng/ml EGF, flash frozen at multiple time points 
post-stimulation, and lysates run on LDS-PAGE in duplicate. All blots included positive and 
negative pY controls to assess non-specific binding. Blots were probed with recombinant GST-
tagged SH2 and PTB probes and an anti-pY antibody (Table 1.1) (38). Of the probes tested, 27 
were selected for further analysis based on significant, reproducible, and dynamic binding to 
EGF-stimulated A431 cell lysates (Figure 1.2). Anti-pY blots of the same lysates showed a rapid 
increase in total phosphorylation upon EGF treatment, dominated by a major band 
corresponding to EGFR (Figure 1.3). Blots also contained a number of minor bands whose 
phosphorylation varied over time. SH2 binding patterns varied across the set of SH2 domains 
tested, however the molecular weights of major bands were consistent, suggesting that most 
SH2 probes bound predominantly to a relatively small set of highly phosphorylated proteins 
(Figures 1.2  and 1.3). Most prominent were five highly dynamic bands, which were identified by 
immunodepletion (Figure 1.4) and exhibited three well-defined kinetic patterns. These major 
bands were (1) EGFR, a ~195kDa band whose phosphorylation increased rapidly following EGF 
treatment, dipped slightly and then remained relatively constant; (2 and 3) the focal adhesion 
protein p130CAS, a doublet at 150 and 115kDa whose phosphorylation was high in 
unstimulated cells, decreased rapidly upon EGF treatment, and then rebounded at later time 
points; (4) the scaffolding protein GAB1, a single band at 130kDa that was phosphorylated with 
kinetics similar to EGFR, then rapidly returned to near basal levels; and (5) the scaffold/adaptor 
SHCA, a relatively weak band at 71kDa which displayed kinetics similar to that of EGFR 
(Figures 1.2, 1.3, 1.4 and 1.5 A). 
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See attached Excel files 
Table 1.1:  SH2 domain constructs. Cloning information and amino acid sequences for all cDNA 
constructs used in this analysis are listed.  
 
36 
 
 
Figure 1.2:  Representative FW blots using 1 PTB and 26 SH2 domain probes for EGF-
stimulated A431 cells. Protein names are labeled on the left and stimulation times are on top. 
For probe names, “-N, -C, or -NC” indicates the use of N-terminal, C-terminal, or natural tandem 
SH2 domain probes. See Table 1.1 for construct information. 
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Figure 1.3. Representative anti-phosphotyrosine blot of EGF stimulation time course in A431 
cells. The major SH2 binding proteins (identified by immunoprecipitation-see 1.4) are marked on 
the left. EGFR and tubulin loading controls shown in lower panels.  
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Figure 1.4 Identification of major SH2 domain binding bands by immunodepletion: A) EGFR, B) 
p130CAS, C) GAB1, and D) SHC1. Blots show expression, phosphorylation and representative 
far-Western for each protein before (pre-ID) and after (post-ID) immunodepletion. 
Immunodepletions were performed on lysates before (0 min) and after (1.5 and 10 min) EGF 
stimulation. 
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Quantification of SH2 domain binding sites 
Far-Western provides a means to characterize the global binding patterns of multiple SH2 
domains across multiple cellular states (38, 67). To quantitatively compare changes in binding 
patterns of different SH2 domains upon EGF treatment, we performed unsupervised hierarchical 
clustering on SH2 domain binding data over the 60-minute EGF stimulation time-course (Figure 
1.5 B). Six distinct SH2 domain-binding clusters (R2 >0.85) were identified, which were broadly 
consistent with literature-reported interactions. For example, GRB2 SH2 and SHCA PTB 
domains most strongly interacted with EGFR (123, 124), SHP2 and p85α/β SH2 domains 
interacted most strongly with GAB1 (125), and focal adhesion-associated proteins such as CRK, 
CRKL, NCK1 and NCK2 bound most strongly to p130CAS (126, 127). All but three SH2 
domains (RASGAP C-terminal, NCK1 and NCK2) showed at least some binding to EGFR. As 
expected, probes from homologous proteins clustered together (i.e. p85 α/β). However, SH2 
probes isolated from proteins with two SH2 domains showed more variation (e.g. RASGAP-N, -
C and -NC) (Table 1.2).  
Tyrosine phosphorylation in EGF-stimulated A431 cells is dominated by phospho-EGFR (see 
Figure 1.3), and as a result most SH2 domains displayed strong EGFR binding. To better 
understand the relative affinity of each SH2 for various phosphoproteins, we normalized the 
quantified SH2 binding signal to pY binding (from anti-pY immunoblot) and reclustered the data 
(Figure 1.6). After normalization, EGFR no longer dominated binding. Only three domains 
(GRB2, SHCA PTB and to a lesser extent ARG) displayed a greater relative affinity for EGFR 
than would be expected from motif-independent pY binding (i.e. anti-pY blotting). Instead, most 
SH2 domains displayed greater than expected affinity for GAB1 and p130CAS. This analysis is 
designed to highlight SH2 binding specificity for particular protein targets; whereas the non-
normalized FW results reflect a combination of binding specificity and the abundance of binding 
sites, and thus are more likely to predict the level of binding to different proteins in vivo.  
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See attached Excel files 
Table 1.2:. Normalized FW, MS and in vivo imaging kinetics data. Normalized Data-Interactive 
tab provides a graph which allows for the comparison of data from FW, MS, imaging and pY 
EGFR immunoblotting. To use, select the desired data from drop down menu. To remove data 
select “Blank” located at the top of the menu. Normalized Data provides source data for the 
interactive chart (top) and all normalized data (below). Errors for FW and MS are shown as 
standard error of the mean and standard deviation, respectively. FW Data displays averaged 
binding quantifications for each SH2 probe. Data for each probe was normalized to the highest 
intensity band on each blot (Data used for Figure 1B). Error used is SEM. The number of 
replicate blots used is listed. MS Data tab provides sequence, Uniprot protein abbreviation and 
protein description for each peptide identified; indication of EGF dependence (two time points 
with Student’s t-test p<.05 and one time point with at least a two-fold increase compared to 
untreated samples); indication of sites not associated with EGF stimulation in PhosphoSitePlus 
database; and the number of biological replicates in which the peptides was detected. 
Phosphosite abundance data is normalized to sum of signal for all eight time points. Error is 
represented as standard or average deviation. 
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Figure 1.5: Dynamic EGF-dependent changes in tyrosine phosphorylation patterns revealed 
by SH2 domain far-Western analysis. A) Representative far-Western blots of 60-minute EGF 
stimulation time-course. Far-Westerns using GRB2, SHP2-N, NCK1 and RASGAP-N are shown 
to illustrate major binding patterns identified (see B) Immunoprepitation identified bands are 
shown to the left. B) Hierarchical clustering of SH2 domains on the basis of binding to four major 
phosphoproteins (EGFR, GAB1, p130CAS, and SHCA). Signal was normalized to maximum 
band intensity across all time points and all bands for each probe (red represents greater 
percentage of total signal, max = 1, min = 0). Names of SH2/PTB domain probes are indicated 
on the right. Colored boxes represent SH2 clusters defined by Pearson correlation coefficient > 
0.85.  
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Figure 1.6: Hierarchical clustering of relative SH2 specificity. Values were obtained by 
subtracting percent bound by pY from percent bound by each SH2 for each time point. Red 
represents binding greater than pY and green represents binding less than pY. Relative SH2 
specificity value = %Band intensitySH2 at time x - %Band intensityanti-pY at time x .   
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pY-EGFR specific SH2 domain binding and downstream signaling 
In principle, if different sites on a particular protein were phosphorylated with very different 
kinetics, different SH2 domains might bind to that protein with different kinetics. For the most 
part, however, we observed only modest differences in the temporal pattern of the binding of 
different SH2 domains to particular phosphoproteins. To better visualize the temporal variation 
in EGFR binding, SH2 domains were clustered based on changes in phospho-EGFR binding 
over time (Figure 1.7A). The majority of probes, including GRB2, ARG, p85 and the SHCA PTB, 
displayed dynamics similar to that of total EGFR phosphorylation, with a rapid and sustained 
increase in binding. However, a set of SH2 domains including CRK, CRKL, RASGAP and 
GRB14 showed a more gradual increase in phosphorylation over the 60-minute time-course. 
And a set of four SH2 domains including EAT2, SHP2-N and the only two Src-family kinases 
(SFK) tested, YES and FYN, displayed a rapid increase in binding followed by a rapid and 
sustained decrease (Table 1.2).  
To test whether this variation was due to binding of SH2 domains to specific EGFR sites 
phosphorylated with different kinetics, we performed EGFR phosphosite-specific Western 
blotting and compared site-specific dynamics to those obtained by FW. Qualitatively, the 
phosphorylation dynamics of specific sites mirrored those of specific SH2 domains by far-
Western (Figure 1.7 A and B). In particular, the kinetics of EGFR pY992, which is located within 
a canonical CRK binding motif (pYXXP), strongly correlated with CRKL probe EGFR binding 
kinetics (R2=0.88). Both displayed an initial rapid rise to approximately half maximum, followed 
by a slow increase to maximum over the 60-minute time-course (Figure 1.7 C). Strong 
correlation was also observed between the dynamics of GRB2 SH2 domain binding and the 
GRB2 binding site EGFR pY1068 (R2=0.91) (Figure 1.7 D) (124). SHCA PTB domain binding 
correlated well with total EGFR pY (R2=0.89), consistent with a recent report suggesting that the 
SHCA PTB binding site on EGFR, pY1148, dominates receptor phosphorylation (111) (Figure  
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Figure 1.7: Comparison of pYEGFR-SH2 binding and EGFR site specific phosphorylation 
dynamics following EGF stimulation.  A) Hierarchical clustering of SH2 binding to EGFR band 
(normalized to maximum, max=1, min=0) for 60-min time-course. B) Hierarchical clustering of 
EGFR phosphosite-specific Western blotting quantifications (normalized to maximum, max=1, 
min=0) for 60-min time-course. C and D) Plots comparing the EGFR phosphosite kinetics and 
SH2 binding kinetics for SH2 domains and their canonical binding motifs (C, CRKL and pY992, 
R2=0.81; D, GRB2 and pY1168, R2=0.91). E) Plot comparing total EGFR phosphorylation (pY 
EGFR band) with SHCA PTB binding (R2=0.89). Correlation coefficients were calculated by 
plotting normalized pY Western intensity against normalized SH2 binding FW intensity. 
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Figure 1.8.   pERK1 and pERK2 pY/pT activation site phosphorylation kinetics following 
stimulation with EGF. Lines represent average of two technical replicates. Data is normalized to 
to maximum =1.   
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1.7 E). However, not all binding data could be predicted from known phosphosite specificities. 
For example, the far-Western binding kinetics of YES, FYN and EAT2 qualitatively resembled 
the rapid and transient phosphorylation EGFR pY974 and pY1045, providing evidence for 
potentially unappreciated interactions (Figure 1.7 A and B, Table 1.2). 
Finally in order to understand the relationship between SH2 binding site creation and 
downstream signaling we assessed the activation time-course of ERK1 and ERK2, which are 
known to be activated after EGF stimulation via recruitment of proteins including SHP2, GRB2 
and SHCA to EGFR (58). Activating phosphorylation of ERK1/2 reached a maximum 
approximately 4 minutes after EGF stimulation, compared with 1.5-2 minutes for tyrosine 
phosphorylation of EGFR (Figure 1.8). 
Quantitative phospho-specific mass spectrometry 
Although SH2-based far-Western blotting provides a unique insight into overall patterns of 
binding for different SH2 domains, it is highly dependent on phosphosite abundance, and does 
not identify specific phosphorylated sites. To obtain a complementary and less concentration-
dependent view of EGF-induced changes in tyrosine phosphorylation, iTRAQ MS was used to 
quantify the phosphorylation kinetics of individual phosphosites. A431 cells were flash frozen 
and lysed at eight representative time points (0, 10s, 30s, 1 min, 1.5 min, 3 min, 10 min, 30 min) 
following EGF treatment. Prior to MS analysis, anti-pY immunoblotting was performed to ensure 
that phosphorylation kinetics and band patterns of MS samples were similar to those used for 
FW analysis (Figure 1.9). Lysates were then digested with protease, enriched for tyrosine-
phosphorylated peptides by anti-pY immunoprecipitation, and purified using affinity 
chromatography prior to analysis by reverse phase liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Relative phosphorylation levels of specific peptides were quantified  
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Figure 1.9  Anti-pY blot of three biological replicates analyzed by iTRAQ phospho-specific MS. 
Eight time points; 0, 0.167, 0.5, 1, 1.5, 3, 10 and 30 min post-EGF were analyzed.  The kinetics 
and phosphorylation pattern observed is very similar to that observed in Figure 1.3.  
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by iTRAQ analysis using three biological replicates; only those phosphopeptides identified in all 
eight time points, in at least two replicates at each time point, were included in our analysis.  
In total, 132 unique pY sites were identified from 93 proteins (Table 1.2). Of the phosphosites 
identified, 88 (67 proteins) displayed an EGF-dependent increase in tyrosine phosphorylation 
(defined by at least one time point with a two-fold or greater increase in abundance and a 
statistically significant increase in at least two time points following EGF treatment), including 
those from EGFR, GAB1 and the SH2-containing proteins SHCA (SHC1), PLC1, SHP2 and 
CRKL (Table 1.2). The percent of EGF-dependent phosphosites indentified in this study (65%) 
was higher than previous experiments using cell lines with more moderate EGFR expression 
(77, 112, 128). Among EGF-dependent sites identified in this study, 64 (57 proteins) were not 
found within a curated database of EGF-dependent phosphosites (62) (Table 1.2).  
Gene ontology (GO)-based functional analysis of EGF-responsive phosphoproteins identified 
enrichment for terms associated with positive regulation of signaling and peptidyl tyrosine 
modification (129). EGF-nonresponsive sites, on the other hand, tended to be associated with 
regulation of cell adhesion and locomotion. However, a large number of terms were shared by 
the two protein sets, indicating significant functional overlap (Figure 1.10). By comparing the 
amino acid frequencies surrounding phosphotyrosines for each group, we found that EGF-
nonresponsive site were more likely to contain the CRK SH2 binding motif (pYXDP/L), 
consistent with the functional association of these proteins with adhesion and locomotion.  EGF-
responsive peptides however, displayed little sequence consensus (Figure 1.11).  
Phosphopeptide analysis of FW-identified proteins  
iTRAQ analysis identified multiple sites from the four major phosphoproteins detected by FW 
(Figure 1.12 and Table 1.2). Comparison of MS and FW data for these proteins  
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Figure 1.10  Venn diagram showing overlap of significant gene ontologies for proteins 
containing peptides whose phosphorylation was enhanced or unchanged by EGF (p<0.05, 
Bonferroni corrected). The number of unique or overlapping ontologies observed for each 
protein set is indicated within the diagram. GO terms listed represent the three largest GO 
parent terms returned by REVIGO (129). 
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Figure 1.11 Amino acid frequency logos for sites whose phosphorylation was enhanced (upper) 
and unchanged (lower) by EGF stimulation. Logos were created with PhosphositePlus logo 
generator.  Amino acid abundance data is realitve to PhosphoSitePlus pY database 
background.   
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revealed both similarities and differences. Four unique EGFR pY peptides and one 
tyrosine/serine dually phosphorylated peptide were identified (Figure 1.12 A). The tyrosine-only 
sites tended to display a continual increase in abundance over the first 10 minutes, compared to 
the more rapid plateau in signal intensity seen in FW and anti-pY (Figures 1.3, 1.9, Table 1.2). 
The dually phosphorylated peptide varied significantly over the time-course and was not scored 
as EGF-dependent. Five unique phosphopeptides were identified for GAB1, all of which 
increased rapidly, but did not show the rapid dephosphorylation seen in anti-pY blots and FW 
(Figure 1.12 B). Like the EGFR pY peptides, the single SHCA phosphopeptide, a known GRB2 
binding site (130), displayed slower phosphorylation kinetics than those obtained from anti-pY 
and FW blots (Figure 1.12 C). MS phosphopeptide data also did not recapitulate the p130CAS 
dephosphorylation and rephosphorylation pattern seen on anti-pY immunoblots and SH2 far-
Western. Instead, the six p130CAS phosphopeptides identified by iTRAQ MS trended toward an 
increase in phosphorylation following EGF stimulation, though only 2 of the 6 displayed a 
statistically significant change in abundance (Figure 1.12 D, Table 1.2). Overall, FW blotting and 
MS-based quantification of individual sites provided rather different perspectives on tyrosine 
phosphorylation dynamics, highlighting the importance of using complementary experimental 
approaches. These results suggest that changes in the binding of an SH2 domain to a multiply 
phosphorylated protein can be difficult to predict precisely from changes in the phosphorylation 
of individual phosphosites on that protein. 
Finally, most phosphopeptides showed a transient decrease in phosphorylation at the 3 min 
time point, similar to the dip seen on far-Westerns and anti-pY Westerns, especially for EGFR 
and SHCA, at approximately 4 min (Figure 1.2, 1.7 C-E and Table 1.2). The fact that a similar 
pattern is seen using two very different experimental approaches increases confidence that it 
accurately reflects the actual behavior of the system.  
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Figure 1.12. Relative MS quantified abundance of phosphosites from major phosphoproteins 
identified by FW. A)  EGFR, B) GAB1 C), SHCA (F) and D) p130CAS (BCAR1). Specific 
phosphopeptide sequences are listed. Abundances are all normalized to maximum = 1.  
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In vivo membrane recruitment of SH2 domains 
FW and MS data revealed dynamic changes in potential SH2 binding sites in response to EGF, 
but provide little insight into the actual binding kinetics of SH2 domain-containing proteins in 
living cells. To address this issue, we quantified SH2 basal membrane recruitment kinetics 
following EGF stimulation in A431 cells for a similar set of 25 SH2 domains, each fused with the 
photoactivatable fluorescent protein tdEOS. TIRF microscopy and sptPALM were used to 
identify SH2 localization patterns and quantify membrane binding, diffusion constants (D) and 
apparent membrane dissociation rates () (Tables 1.2 and 1.3). It is important to note that all 
SH2-containing proteins contain additional interaction domains that may affect the recruitment 
kinetics of the full length proteins in vivo; however in order to directly compare results with SH2 
binding site data from the FW and MS studies above, we assayed in vivo binding using isolated, 
ectopically expressed SH2 domains. In the case of GRB2, we previously showed that full-length 
GRB2 and the SH2 domain alone were very similar in their in vivo membrane binding behavior 
(94), indicating that for this protein the kinetics were dominated by SH2-pY interactions. 
Live-cell imaging of EGF-induced SH2 domain membrane binding revealed a wide variety of 
dynamic behaviors among the different SH2 domains tested. However, a number of trends were 
apparent in light of the binding specificities identified by FW hierarchical clustering. SH2 
domains that predominantly bound GAB1 (e.g. SHP2-C/-NC, SHIP2) tended to reach maximum 
binding rapidly, diffuse rapidly upon binding, and display a relatively diffuse spatial distribution 
before stimulation, and a mix of clustered and diffuse localization after stimulation. EGFR-
binding SH2 domains (e.g. GRB2 and GRB7) displayed relatively slow recruitment kinetics and 
diffusion rates, and their binding sites tended to cluster together into discrete foci in response to 
EGF. p130CAS-binding domains (e.g. CRK, NCK, PLC-C) generally had either slower 
recruitment kinetics or exhibited small to no net recruitment following stimulation; they also 
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Table 1.3: Quantification of in vivo SH2 binding dynamics and binding site kinetics.  To directly 
compare FW and in vivo imaging data, both SH2 binding site phosphorylation and in vivo SH2 
membrane recruitment curves were fit to the first order exponential recovery function (1-e-t/), 
where  is the binding time constant and t is time after EGF. D is the average diffusion rate of 
SH2 molecules on the membrane.  is the apparent membrane dissociation rate constant. 
Decay identifies those SH2 domains with decreasing apparent dissociation rate constants (i.e. a 
decaying hazard rate function). * denotes data which fit poorly to the recovery function (R-
square < 0.5).  ND denotes data which was not determined. SEM reported in parentheses.   
  
in vivo (single molecule and TIRF 
imaging)  
in vitro (FW 
 
SH2 Domain 
 
recruitment 
time  (min) 
(s-1) D (m2/s) 
 
phosphorylation 
time  (min) 
 
SHIP2 
 
0.55 (0.15) decay 0.04 
 
1.13 (0.81)*  
SHP2-N 0.91 (0.02) 0.96 0.187 0.60 (0.01)  
GRB14 0.99 (0.47) decay - -1.50 (0.08)  
SHP2-NC 1.57 (0.18) decay 0.081 1.57 (0.18)  
SHP2-C 1.85 (0.49) 2.16 0.759 ND  
EAT2 2.26 (1.10) 1.48 0.097 0.64 (0.51)*  
PLC1-NC 2.44 (0.18) 1.01 0.022 0.62 (0.19)  
p85-NC 3.06 (0.32) 0.31 0.004 0.51 (0.09)  
SHC PTB 3.25 (0.08) 0.36 0.007 0.69 (0.08)  
GRB7 3.45 (0.67) 0.46 0.009 0.77 (0.05)  
VAV2 4.27 (0.52) 0.64 0.034 0.80 (0.17)  
SHC SH2 4.57 (0.20) 0.64 0.026 ND  
GRB2 4.58 (0.41) 0.59 0.021 .059 (0.03)  
PLC1-N 5.15 (2.28) 0.08 0.022 0.75 (0.33)  
CRK 5.54 (0.64) 0.2 0.016 -2.80 (0.29)  
RASGAP-NC 5.92 (0.80) decay 0.076 -1.27 (0.54)*  
PLC1-C 6.48 (1.27) 0.029 0.043 0.30 (0.03)  
ARG 6.55 (0.90) decay 0.01 0.54 (0.20)  
p85-N 6.88 (0.78) decay 0.016 0.67 (0.10)  
RASGAP-N 6.99 (2.53) 0.44 0.011 -2.51 (0.98)  
FYN constant ND 0.008 0.43 (0.04)  
NCK1 decrease ND 0.009 -0.83 (0.03)  
RASGAP-C constant ND ND 1.27 (0.54)*  
ABL constant ND ND 0.70 (0.40)  
YES ND ND ND -3.62*(1.48)  
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primarily localized to structures resembling focal adhesions (Figures 1.13A, 1.14 A-C, Tables 
1.2 and 1.3).  
To compare SH2 recruitment kinetics of different SH2 domains, time constants were calculated 
for the recruitment curves obtained for each SH2 domain. Membrane fluorescence 
measurements following EGF treatment were plotted with respect to time and fitted to the first 
order exponential recovery function, 1-e(-t/), where t equals the EGF stimulation time. The time 
constant () is proportional to the time required to reach maximal binding. SH2 domain 
membrane recruitment time constants negatively correlated with both disassociation and 
diffusion rates (Table 1.3, Figure 3, Figure 1.14 D and E). In other words, those SH2 domains 
that were recruited most quickly tended to have the highest apparent diffusion and dissociation 
rates after binding.  
One surprising result was that for most SH2 domains, in vivo binding kinetics lagged 
significantly when compared to the kinetics of SH2 binding site creation, as measured by far-
Western (Figure 1.13 B, Table 1.2). On average, time constants calculated from membrane 
fluorescence intensity were ~6 times greater than time constants for the same domains 
calculated from far-Western blotting, and in vivo time constants had a much greater range when 
compared with those obtained by FW (Table 1.3). This lag was unexpected, as simple 
calculations using best-estimate SH2 concentrations and rate constants (kon and koff) suggested 
that binding and unbinding should equilibrate rapidly, within seconds. Using the GRB2 SH2 as 
an example, we examined two potential mechanisms that could give rise to this discrepancy, 
both which of turned out to be unsubstantiated. First, unexpectedly low concentrations of GRB2 
SH2-tdEOS and phosphorylated EGFR in vivo could prolong the time to EGF-induced 
equilibrium. However, direct biochemical measurements of GRB2 SH2-tdEOS and pY-EGFR in 
these cells (6.5 μM and 1.5 μM, respectively) did not support this theory (Figure 1.15). 
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Figure 1.13: In vivo localization and recruitment kinetics of SH2 domains. A) Representative 
total internal reflection fluorescence (TIRF) microscopy images of fluorescently tagged SH2 
domains before and 40 min after EGF stimulation, for SHP2-N, GRB2, NCK1 and RASGAP-N 
SH2 domains. B) Comparison of change in total membrane SH2 fluorescence from imaging live 
cells (red) and change in FW-based SH2 binding (black) following EGF stimulation. Gray lines 
indicate TIRF background signal. Data is normalized to maximum.  
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Figure 1.14 Analysis of in vivo SH2 domain localization and membrane binding. A-C) TIRF 
images of fluorescently tagged SH2 domains before and after EGF stimulation. A) GAB1 
binding domains B) EGFR binding domains, and C) p130CAS binding domains. Domains were 
grouped according to clustering results from Figure 1B. Post-EGF images were taken ~40min 
after stimulation. D) Correlation of SH2 domain apparent membrane off-rate (, y-axis) and SH2 
domain membrane recruitment time constant (, x-axis). E) Correlation plot of SH2 domain 
probe diffusion rate (D, y-axis) and recruitment time constant (, x-axis). Data for SHP2-C was 
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an outlier and was removed from the plot for clarity. F) CRK FW time-course blots from A431 
and COS1 cells simulated in parallel with 10 ng/mL EGF. CRK SH2 shows little or no binding to 
the EGFR band in COS1 cells.  
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Then, we ruled out the possibility that SH2 binding site creation on the basal membrane (where 
in vivo binding is measured by TIRF) is much slower than on the apical membrane by 
quantifying confocal images of EGF-stimulated cells immunostained with anti-pY antibody 
(Figure 1.16).  
It is also worth noting that most p130CAS-binding domains showed increased membrane 
binding in response to EGF, even as total binding site availability (as measured by FW) declined 
over the first 5-10 minutes (Figure 1.2, Table 1.2). This is likely the result of the relatively high 
concentration of EGFR phosphosites in the EGF-stimulated A431cells (Figure 1.14 F). One 
exception however was NCK1 SH2, which did in fact display an initial decrease in membrane 
binding upon EGF treatment, though it did not exhibit the late increase (10-60 min) or occur at 
the same rate seen in FW (Figure 1.13 B, panel 3, Table 1.2). Nevertheless, multiple 
parameters obtained from in vivo imaging were consistent with p130CAS being the major NCK1 
SH2 binding partner. Diffusion and motility measurements of fluorescent p130CAS and NCK1 
SH2 were remarkably similar (Figure 1.17 A and B). In addition, composite images created from 
sptPALM movies showed both the NCK1 SH2 domain and p130CAS localizing to focal 
adhesion-like structures on the cell periphery (Figure 1.17 C). Taken together, these results 
suggest that the SH2 domain binding in vivo is a phosphosite-dependent, but not fully 
equilibrated, process. 
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Figure 1.15 . Quantification of GRB2 SH2-tdEOS in A431 cells. A) Representative white light 
(top panel) and epifluorescence images (lower panel) of GRB2 SH2-tdEOS transfected A431 
cells that were used to determine total cell number, transfection efficiency and relative 
expression level. Insert (upper panel) shows representative DIC image of nonadherent cells 
used to determine cell volume. B) Histogram of individual cell GRB2 SH2-tdEOS expression 
levels. Left skew in expression was compensated for in the final calculation. C) Anti-GRB2 SH2 
blot used to calculate average GRB2 SH2-tdEOS concentration D) Anti-pY blot showing EGF-
induced EGFR phosphorylation and phosphorylation standard titration used to calculate the 
cellular concentration of phosphorylated EGFR sites.  
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Figure 1.16 Quantification of pY on the basal membrane of A431 cells following EGF. A) 
Representative z-axis cross-sections of fixed A431 cells immunostained with anti-pY. The 
images and traces were obtained from the same cell along the x- and y-axes. White block 
indicates the quantified area. Curves represent an average of multiple line scan quantifications 
across an individual cell membrane. B) Apical and basal pY levels following EGF stimulation as 
measured by immunofluorescence.  Intensity measurements from at least 10 cells were 
averaged for each time point. C) Ratio of apical to basal phosphorylation following stimulation 
with EGF. 
  
62 
 
 
 
 
Figure 1.17.  In vivo NCK SH2 and p130CAS display similar membrane interaction dynamics.  
A) Histogram of individual NCK1 and p130CAS molecule diffusion rates post-EGF. B) Mean 
square displacement (MSD) plots of p130CAS (black) and NCK1 SH2 domain (red) post-EGF. 
C) sptPALM images of tdEOS-labeled p130CAS and NCK1 SH2-tdEOS in A431 cells before 
EGF stimulation. 
  
63 
 
Changes in total cellular phosphorylation correlate with the apparent SH2 on-rate  
If SH2 membrane binding in vivo is indeed far from equilibrium, then maximum phosphorylation 
and maximum binding need not be coincident. Instead, maximum phosphorylation may be more 
closely correlated with the maximum rate of recruitment, i.e. on (t) = kon(t)[pY][SH2], where on (t) 
is the apparent on-rate at time t. To test this we directly measured the rate of binding by utilizing 
 sptPALM to count the number of new SH2 molecules appearing at the membrane during a 
small time window (97). For these experiments, we utilized the GRB2 SH2 domain to minimize 
effects from binding to non-EGFR phosphoproteins (Figure 1.2 and 1.5). Using this method we 
found that the binding rate of GRB2 SH2 increased much more rapidly (=2.08 min) than total 
binding (Figure 1.18 A, black line). To corroborate this rate measurement, we attempted to 
recapitulate the experimentally obtained changes in GRB2 SH2 abundance at the membrane by 
combining apparent on-rate measurements, with apparent off-rate measurements (off) 
calculated using a previously published method (Figure 1.18 A, red line) (94). This relationship 
can be represented as follows: 
   
d[mem:SH2]
dt
= 𝛾𝑜𝑛(𝑡) − 𝜆𝑜𝑓𝑓(𝑡) ∙  [𝑚𝑒𝑚: 𝑆𝐻2](𝑡)  (1) 
The solution of this nonhomogeneous first order differential equation being: 
[mem: SH2](t) = ce− ∫ 𝜆𝑜𝑓𝑓(t)dt + e− ∫ 𝜆𝑜𝑓𝑓(t)dt ∫ 𝛾𝑜𝑛 (t) · e
∫ 𝜆𝑜𝑓𝑓(t)dtdt    (2) 
Plugging in the measured values for 𝛾𝑜𝑛(𝑡) and 𝜆𝑜𝑓𝑓(𝑡) for GRB2 SH2 returns a SH2 membrane 
binding [Mem:SH2] curve with a relatively slow rate of recruitment. This rate was similar to that 
obtained experimentally (Figure 1.18 B), indicating that SH2 recruitment is likely kinetically 
controlled and not an equilibrated process.  
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GRB2 SH2 domain binds rapidly to non-clustered sites 
We previously reported that clustering of SH2 binding sites was associated with a decrease in 
the apparent membrane dissociation rate (increase in dwell time) (94). We proposed that this 
was due to increased SH2 rebinding to phosphosites that were more closely packed upon 
clustering. It was therefore plausible that clustering might play a role in the apparent delay in 
maximal recruitment of SH2 domains to membrane binding sites. Consistent with this idea, 
analysis of GRB2 SH2 cluster size and cluster number in EGF-treated cells showed that cluster 
formation reaches a maximum at 10-15 min (Figure 1.18 C), a time-scale coincident with that of 
the recruitment of GRB2 SH2 to the cell membrane. Furthermore, as mentioned above, we 
found that the recruitment time constants for individual SH2 domains negatively correlated with 
their apparent dissociation rates, which we previously reported to depend on the extent of 
phosphosite clustering (Figure 1.14 D, Table 1.3) (94). These results suggested that maximal 
membrane recruitment of SH2 domains may lag behind the generation of phosphorylated SH2 
binding sites due to the relatively slow clustering of those sites.  
To assess more directly the role of clustering in SH2 recruitment kinetics, we counted the 
number of molecules detected within cluster regions on sptPALM images. We found that the 
binding rate within clusters increased at a relatively a slow pace, reaching maximum at 
approximately 10.5 min, with a time constant of cluster = 4.05 min (Figure 1.18 D, red). In 
contrast, the binding rate in non-cluster regions, obtained by subtracting cluster-associated 
binding events from the total binding events detected, reached a maximum at approximately 2.5 
min (non-cluster = 1.08 min) (Figure 1.18 D, blue). These results strongly suggest that binding to 
non-clustered phosphosites is relatively fast and tracks with the level of phosphosites available, 
while increases in in vivo binding seen at later points (after 1-2 minutes) can be attributed to 
increased binding to clustered sites as they accumulate. 
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Figure 1.18. New molecule membrane recruitment and cluster-associated recruitment in vivo. 
A) Apparent membrane binding rate (gon, black line) and apparent membrane dissociation rate 
(loff, red line) following stimulation with EGF. B) SH2 membrane binding curve calculated using 
experimentally determined gon and loff values. C) Kinetics of GRB2 SH2 binding site clustering 
(cluster size x cluster number) after EGF treatment. D) Number of newly recruited GRB2 SH2 
molecules (black, whole), and those within clusters (red, cluster) and outside of clusters (blue, 
non-cluster) after EGF stimulation. Dotted lines show fit with exponential recovery function.   
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Pervanadate-treated cells display reduced GRB2 binding site clustering and rapid 
recruitment 
To further validate the relationship between SH2 recruitment and EGFR clustering, we sought a 
way to measure GRB2 SH2 domain recruitment in the absence of clustering. Binding of EGF to 
EGFR has been shown to induce dimerization, as well as higher order clustering of the receptor 
in a kinase-activity-dependent manner (60, 115, 119, 120). We attempted to bypass EGF-
induced receptor multimerization by treating cells with the competitive irreversible tyrosine 
phosphatase inhibitor pervanadate (PV), which increases cellular pY levels by blocking 
dephosphorylation. PV treatment led to a rapid increase in phosphotyrosine on a large number 
of proteins as shown by anti-pY immunoblot, but FW blotting with the GRB2 SH2 demonstrated 
that the EGF receptor was by far the major GRB2 SH2 binding protein in PV-treated cells 
(Figure 1.19 A). We confirmed the lack of GRB2 SH2 binding site clustering in PV-treated cells 
using a variety of measures. Firstly, GRB2 SH2-tdEOS showed a diffuse spatial distribution in 
PV-treated cells (Figure 1.19 B). Secondly, individual membrane-associated GRB2 SH2 
molecules were much more mobile (i.e. had a higher diffusion rate) in PV-treated cells than in 
cells treated with EGF (Figure 1.19 C). Finally, the apparent dissociation rate of GRB2 SH2 was 
significantly greater in PV-treated cells (Figure 1.19 D). These results were all consistent with a 
lack of GRB2 SH2 binding site clustering in PV-treated cells. 
In the absence of apparent binding site clustering, GRB2 SH2 membrane recruitment in PV-
treated cells occurred rapidly (=0.81 + 0.15 min) (Figure 1.19 E).  The rate of membrane 
binding in these cells was comparable to the rate of GRB2 binding site creation in PV-treated 
cells, as measured by GRB2 FW (Figure 1.19 A, E, G). New molecule recruitment was only 
marginally faster (=0.58 ±0.17) than total recruitment, indicating that little or no GRB2 SH2 
rebinding was occurring at the plasma membrane (Figure 1.19 F). These results are consistent 
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with the interpretation that delayed SH2 domain binding kinetics in EGF-treated cells are the 
result of increased binding site clustering over time. 
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 Figure 1.19. GRB2 SH2 recruitment in pervanadate (PV) treated cells. A) Representative 
GRB2 SH2 far-Western and anti-pY immunoblot for EGF and PV treated cells. B) TIRF 
microscopy images of fluorescently tagged GRB2 SH2 in pervanadate-treated (PV)- and EGF-
stimulated cells 40 min post-stimulation. C) Mean square displacement (MSD) of GRB2 SH2 in 
EGF- (black) and pervanadate-treated cells (red). D) Change in mean apparent membrane 
dissociation (i.e. hazard rate, ) of GRB2 SH2 following EGF and PV treatment. E) TIRF 
imaging of total GRB2 SH2-tdEOS fluorescence following PV treatment for two separate cells. 
F) New molecule recruitment rate (apparent on-rate) curves for two separate PV-treated cells. 
G) Plot of GRB2 membrane fluorescence kinetics (TIRF imaging, see E) and GRB2 FW (n=2) 
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total binding in EGF-treated cells (red-in vivo, black-FW) and PV-treated cells (magenta-in vivo, 
blue-FW). FW data is normalized so that the maximum signal in EGF treated cells equals 1. 
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Discussion 
In this study we employed three methods to monitor EGF-induced tyrosine phosphorylation and 
SH2 domain binding in the EGFR overexpressing A431 cell line: far-Western blotting, iTRAQ 
MS, and in vivo imaging of plasma membrane SH2 domain recruitment. These methods proved 
to be complementary and far from interchangeable, as response kinetics showed surprising 
differences. Nevertheless, by combining and comparing data from each technique we were able 
gain unique insights into the relationship between protein tyrosine phosphorylation, creation of 
SH2 domain binding sites, and membrane recruitment of SH2 domains in response to EGF, as 
well as into the capabilities of each method.  
FW data provided an unprecedented global overview of changes in binding sites for 27 
representative pY binding domains in response to EGF. A unique aspect of the FW approach is 
that it provides insight into the overall binding preferences of particular SH2 domains among all 
the tyrosine phosphorylated proteins in a cell lysate. Our results are generally consistent with 
previously reported SH2 domain-phosphoprotein interactions. On the whole, however, EGFR 
binding dominated SH2 probe binding patterns in our experiments. For example, probes such 
as CRK and CRKL, which are generally considered specific for focal adhesion proteins, 
displayed significant EGFR binding. This is likely due in part to the high EGFR expression level 
in A431 cells. When the CRK SH2 domain was used to probe far-Western blots of EGF-
stimulated COS1 cells, which express more typical amounts of EGFR, strong p130Cas binding 
was seen in the absence of significant binding to EGFR (Figure 1.14 F). This suggests that the 
concentration of SH2 domain binding sites can be as important as SH2 domain binding 
specificity for determining the output of tyrosine kinase signaling pathways, and is consistent 
with the idea that signaling pathways can be “re-wired” by dysregulated RTK activity (131).  
By temporally resolving both short and long stimulation time points, we were also able to show 
that the time course of phosphorylation can differ when specific EGFR sites are compared. This 
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was demonstrated by EGFR phosphosite-specific immunoblotting, and was reflected in the 
differences observed in SH2 binding site kinetics by far-Western blotting. These results suggest 
that the stoichiometry of SH2 and PTB domain-containing effectors bound to EGFR is 
temporally regulated by differential phosphorylation/dephosphorylation of their specific binding 
sites following stimulation with EGF. However, these differences were generally modest, and as 
such, evaluation of their importance for EGFR signaling will require a more in-depth analysis. 
Nevertheless, for multiply phosphorylated proteins, such as EGFR, far-Western likely provides a 
more complete picture of SH2-mediated signaling than phosphosite-specific Western blotting 
alone, because many SH2 domains display at least some affinity for multiple phosphosites on 
these proteins, and the relative stoichiometry of phosphorylation of different sites is variable and 
is challenging to quantify (43, 111).  
Using iTRAQ MS we were able to show that the phosphorylation state of over 65% of observed 
pY peptides was significantly altered following EGF stimulation, a much higher percentage than 
detected in previous studies using similar significance thresholds in cell lines with more 
moderate EGFR expression. Many of these sites are not listed as EGF-dependent within the 
PhosphoSitePlus database. Again, these data suggest that EGFR overexpression is associated 
with a significant expansion of its classical downstream signal transduction pathways. However, 
a more systematic analysis is needed to validate and quantify the effects of receptor expression 
level on EGFR signalosome plasticity. iTRAQ MS was also able to identify functional differences 
in protein tyrosine phosphorylation. GO analysis revealed significant differences between EGF-
dependent and -independent phosphoproteins. As expected, proteins with EGF-dependent 
phosphosites were associated with ontologies related to activation of pY-dependent growth 
factor signaling. On the other hand, proteins containing non-affected sites tended to be 
associated with ontologies related to integrin signaling and cellular adhesion. Phosphosites in 
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these unaffected proteins were also more likely to contain CRK or NCK binding sites, consistent 
with their role in cell adhesion signaling.  
The relatively fine temporal resolution of our analyses allowed us to capture small dynamic 
changes in protein tyrosine phosphorylation that were likely missed by previous studies using 
broader time intervals. Of particular note is the oscillation in the tyrosine phosphorylation levels 
soon after stimulation with EGF. The phenomenon was reproducibly captured for EGFR and to 
a lesser extent GAB1 by anti-pY and far-Western blotting. The observation of a similar dip in 
most MS-detected phosphosites suggests that it is a general feature of EGF-induced tyrosine 
phosphorylation and not a methodological artifact. While we can only speculate about the 
specific mechanism, it is likely due to feedback mechanisms that function rapidly and are 
directly linked to EGFR kinase activity (e.g. recruitment of SH2-containing phosphatases (Ferrell 
and Ha, 2014)). Moreover, such phosphorylation-dependent phosphatase-mediated negative 
feedback could also explain why the phosphorylation of SH2 domain-containing proteins, such 
as SHCA, reached equilibrium long before their recruitment to the membrane reached a 
maximum. EGF-dependent recruitment or activation of phosphatases might serve to counter the 
effect of the continued increases in binding between SH2-containing proteins and EGFR, as 
detected by TIRF imaging.  
We also observed a number of inconsistencies between MS and far-Western in phosphorylation 
kinetics. This was particularly true for the focal adhesion scaffold p130CAS, where individual 
phosphosites did not show the decline in abundance after EGF treatment seen in FW (and anti-
pY) blots. Similarly, we also observed noticeable differences in the rate of phosphorylation of 
sites on EGFR when compared to matched anti-pY Westerns. How can different analytic 
methods give such different results for the same samples? It is important to realize that both FW 
and anti-pY blots integrate the total signal for all phosphosites on a given protein, which can 
vary widely both in their affinity for different SH2 domains and in their stoichiometry of 
73 
 
phosphorylation. Discrepancies can arise when the limited subset of phosphosites detected by 
MS is not phosphorylated and/or dephosphorylated with the same kinetics or to the same level 
as the totality of sites that contribute to Western or far-Western signals. This is more likely to be 
an issue for proteins with many potential phosphorylation sites, such as EGFR and p130CAS 
(Table 1.2, Figure 1.17 A and B). More directed analyses of specific multiply phosphorylated 
proteins will be needed to resolve this question definitively.  Nevertheless, these findings 
highlight the need to use multiple orthogonal methods to gain a full and accurate picture of the 
molecular events downstream of RTK activation.  
Perhaps the most notable and surprising finding from this study was the difference between the 
kinetics of SH2 binding site creation, as measured by FW, and in vivo membrane recruitment, 
as measured by live cell imaging. The average time required for membrane binding to reach a 
maximum following EGF stimulation was nearly six times longer than expected based on the 
abundance of binding sites, indicating that SH2 membrane recruitment is not in rapid equilibrium 
with tyrosine phosphorylation. The extent of the apparent lag in in vivo binding correlated to 
some extent with SH2 binding specificity and the diffusion rate of bound SH2 domains—in 
general, the lag was shorter for SH2 domains that bound mostly to GAB1. Furthermore, the 
extent of the lag was also correlated with the apparent membrane off-rate, in that the SH2 
domains with the longest membrane dwell times were also typically those that took the longest 
to reach maximal binding (Figure 1.14 D). We recently reported that the apparent membrane 
off-rate is related to the clustering of SH2 binding sites, as clustering favors phosphosite 
hopping or rebinding at the membrane (94). The results presented here suggest that clustering 
plays a role in the apparent delay in reaching maximal SH2 binding in vivo and that this delay 
may be a natural feature of the interaction between SH2 domain-containing proteins and the 
membrane. Consistent with this hypothesis, the time-course of GRB2 SH2 binding site 
clustering in response to EGF was remarkably similar to the time-course of membrane 
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recruitment (Figures 1.13 B and 1.18 C). Moreover, when GRB2 binding sites were created 
without inducing clustering (by PV treatment), the apparent delay was no longer seen, and the 
rates of GRB2 binding site formation and membrane recruitment were nearly equal (Figure 1.19 
G).  
We were able to directly measure the effect of rebinding by using sptPALM to quantify the 
recruitment of new domains to the membrane (equivalent to the effective membrane on-rate). 
The new molecule membrane binding rate (i.e. the apparent on-rate) reached a maximum much 
more quickly than did total membrane binding. In particular, the kinetics of new molecule binding 
to unclustered sites were very similar to the kinetics of binding site generation measured by far-
Western (Figure 1.18 D, Table 1.2). This strongly suggests that the apparent delay in total 
membrane binding observed under TIRF microscopy is the result of changes in the effective off-
rate, and not an issue of binding site availability.  
This novel observation of a lag in reaching maximal recruitment to phosphorylated sites in vivo 
raises the question of how such a delay might impact signaling. Signal outputs are subject to 
multiple positive and negative feedback loops, making it difficult to assess the specific role of 
such a phase delay. For example, our results show that ERK activation (assayed by ERK1/2 
phosphorylation) reaches a maximum at ~4 min, between the time of maximal GRB2 binding 
sites (1-2 min) and maximal recruitment of GRB2 to the membrane (~10 min). It is possible that 
the sustained, clustering-dependent increase in SH2 binding might be involved in regulating the 
duration of ERK activation. Alternatively, it may be more important in the response to lower 
(more physiological) levels of receptor stimulation than those used for our experiments. Another 
interesting possibility is that clustering-dependent recruitment is a mechanism to diversify the 
response kinetics upon receptor stimulation. For example, recruitment of effectors to GAB1, a 
relatively freely diffusing scaffold protein, reaches a maximum much more rapidly than 
recruitment of effectors to EGFR itself. Phosphorylation of scaffolding and adaptor molecules 
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such as GAB1, SHCA, and others may play a general role in increasing the spatiotemporal 
diversity of receptor output (75, 133). 
Taken together, the data presented here provide a strong rationale for a multimodal approach to 
the analysis of PTM-mediated signaling. Such an approach allows the identification of areas of 
discrepancy, which can then be explored by more directed experimentation. This is analogous 
to the interplay between in vivo experimentation and computational modeling, where new insight 
is driven by discrepancies between model predictions and experimental results (134, 135). In 
the process of reconciling seemingly discordant results obtained by interrogating the same 
system with multiple methodologies, one can gain novel insights into the system not possible 
from studies dependent on a single methodology.  
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Abstract: 
Phosphotyrosine (pY) dependent signaling is a highly dynamic process. Signal output depends 
not only on rates of phosphorylation and dephosphorylation, but also on rates of binding and 
dissociation of effectors containing phosphotyrosine-dependent binding modules such as Src 
Homology 2 (SH2) and phosphotyrosine binding (PTB) domains. Previous in vitro studies 
suggested binding of SH2 and PTB domains can enhance protein phosphorylation by protecting 
bound sites from phosphatase-mediated dephosphorylation. To test whether this occurs in vivo, 
we quantified the effects of SH2 domain overexpression on protein tyrosine phosphorylation by 
quantitative Western and far-Western blotting, mass spectrometry (MS), and computational 
modeling, using the binding of GRB2 (growth-factor receptor bound 2) to phosphorylated 
Epidermal Growth Factor Receptor (EGFR) as a model system. We found that SH2 
overexpression resulted in a significant, dose-dependent increase in EGFR tyrosine 
phosphorylation, and the phosphosites enhanced corresponded with the binding specificity of 
the overexpressed SH2 domain. Computational modeling using experimentally determined 
EGFR phosphorylation rates, and pY-EGFR and GRB2 concentrations recapitulated 
experimental findings. Surprisingly, both modeling and biochemical analysis suggested that SH2 
domain overexpression did not result in a major decrease in the number of unbound 
phosphorylated SH2 domain binding sites. Our results suggest that signaling via SH2 domain 
binding is buffered over a relatively wide range of effector concentrations, and that SH2 domain 
proteins with overlapping binding specificities are unlikely to compete with one another for 
phosphosites in vivo. 
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Introduction: 
SH2 (Src-Homology 2) domains are small modular protein domains that bind specifically to 
tyrosine phosphorylated sites on proteins (32, 34). In cell signaling, proteins that contain SH2 
domains function to “read” post-translational marks that are “written” by activated tyrosine 
kinases and are “erased” by protein tyrosine phosphatases (PTPs) (136). Protein complexes 
mediated by SH2-phosphotyrosine (pY) interactions are critical for downstream signaling from a 
number important tyrosine phosphorylated proteins, including activated receptor tyrosine 
kinases (RTKs) such as the Epidermal Growth Factor Receptor (EGFR) and the proteins 
phosphorylated by RTKs as well as by non-receptor cytoplasmic tyrosine kinases, such as Abl 
and Src; (107, 108).  
In total, 120 unique SH2 domains have been identified in 110 proteins with varying functions 
including adaptors, tyrosine and serine/threonine kinases, tyrosine phosphatases, and lipid 
phosphatases (107). SH2 binding specificity and affinity is defined by the amino acid sequence 
flanking their pY binding site. In particular, amino acids at positions -1 through +3 relative to the 
phosphotyrosine have been shown to have the greatest influence. While the specificity of each 
SH2 domain is unique, most SH2s bind to one of a few general motifs; +1 D/E, +2 N, +3 P/L/V, 
and +1M +3M (35, 36, 110). SH2 domain phosphosite motif specificities and affinities have been 
elaborated using in vitro methods such as surface plasmon resonance, solution assays and 
protein microarray, and using pull-down based approaches (43, 89, 137, 138). In addition to 
SH2 domains, there are a relatively small number of other phosphotyrosine-specific binding 
modules which include several PTB (phosphotyrosine binding) domains (139, 140). 
SH2 binding in vivo is highly dynamic (49, 141). Not only do SH2 domains bind and unbind from 
phosphosites rapidly at rates determined by their binding constants, but phosphosites 
themselves turn over rapidly, with halftimes in the range of seconds (49). The rate of 
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phosphosite turnover is dependent on both kinase and phosphatase activity (142). Furthermore, 
multiple SH2 domains are expressed and can compete for binding to phosphosites. Thus 
understanding SH2-mediated signal output requires consideration of phosphotyrosine flux and 
local concentrations of SH2-containing proteins, in addition to binding site specificity.  
To study the interplay between SH2 domain binding and phosphosite dynamics we have 
exploited EGFR, a major docking site for multiple SH2 domain containing proteins. EGFR 
kinase activity increases when its ligand, EGF (Epidermal Growth Factor), binds to the 
extracellular domain of EGFR inducing structural changes that promote receptor dimerization 
and kinase activation (142). As a result, cellular levels of EGFR kinase activity can easily be 
manipulated by varying ligand concentration. Moreover, unlike most kinases, EGFR kinase does 
not depend on tyrosine phosphorylation of the so called activation loop. This is important 
because the effects of SH2 expression on receptor phosphorylation can be assessed 
independent from phosphorylation-associated receptor activation (48, 59, 61, 143, 144). 
Activated dimerized receptors phosphorylate the C-terminal tyrosine residues that serve as 
binding sites for a set of SH2 domain-containing proteins including GRB2, SHCA, PLCγ1 and 
SHP2 (43, 66, 145). Each SH2 domain is thought to bind preferentially to a specific individual 
phosphosite or subset of phosphosites based on its individual binding specificity. For example, 
GRB2 has been shown bind to pYXN motifs (where X can be any amino acid) at EGFR pY1068, 
pY1086 and pY1114, while the SHCA PTB domain has been shown to bind strongly to pY1148, 
a NPDpY motif (35, 124, 146, 147). 
Previous studies suggested that SH2 domains could specifically prevent dephosphorylation of 
their phosphosite binding partners in vitro (148–151). However little is known about the impact 
in living cells, where phosphosite turnover is high and overall occupancy may be low. Here we 
use EGFR, as well as constructs containing the GRB2 and CRK (v-Crk avian sarcoma virus 
CT10 oncogene homolog) SH2 domains, to investigate the interplay between SH2 domain 
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binding and phosphosite dynamics in vivo, focusing specifically on a quantitative analysis of 
phosphosite protection. By employing biochemical analyses, phosphotyrosine-specific mass 
spectrometry (MS) and computation modeling we demonstrate that GRB2 can enhance the 
steady state tyrosine phosphorylation level of its binding sites in vivo through SH2-dependent 
protection from PTPs. Our results also suggest that SH2 protection has important implications 
for our understanding of binding site competition between SH2 domains with similar 
specificities. Furthermore, SH2-mediated pY protection might serve as the basis for a novel 
method for identifying SH2-pY interactions as they occur in vivo. 
 
Results: 
GRB2 SH2 domain overexpression enhances EGFR phosphorylation 
To assess the effect of SH2 protein-phosphosite interaction on tyrosine phosphorylation we 
transiently overexpressed full-length wild type (wt) GRB2 in COS1 cells and monitored cellular 
tyrosine phosphorylation before and after stimulation with EGF (2.5ng/mL for 5 min) by anti-pY 
Western (Figure 2.1 A and 2.1 B lanes 1-4). GRB2 overexpression enhanced total EGFR 
phosphorylation before and after EGF treatment. Relative increases in pY-EGFR ranged 
between 1.5 and 4 fold and were more pronounced following EGF treatment.     
GRB2 mediates signaling through a complex series of downstream pathways and it is possible 
that these pathways could lead indirectly to enhanced EGFR phosphorylation, for example by 
increasing cytoplasmic kinase activity or suppressing phosphatase activity (152–155). To rule 
out downstream signaling as a driver of GRB2-mediated EGFR phospho-enhancement, we 
compared protein tyrosine phosphorylation after expression of wt GRB2 with four GRB2 derived 
constructs: a fluorescently tagged GRB2 SH2 domain (tdEOS-GRB2 SH2), previously shown to 
be recruited to the plasma membrane of EGF stimulated cells; full length GRB2 and tdEOS-
GRB2 SH2 constructs containing a mutation in the SH2 domain (R86K), previously shown to 
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abrogate phospho-dependent interaction; and a chimeric protein in which the SH2 domain of 
GRB2 is replaced by that from CRK, referred to here as GCG (Figure 2.1 A and 2.1 B lanes 5-
12) (94, 151, 156). Unlike the GRB2 SH2, which binds predominantly to the activated EGFR, 
the CRK SH2 domain binds predominantly to phosphorylated p130CAS, and only weakly to 
phosphorylated EGFR (157).  
As expected, SH2 constructs carrying the R86K mutant failed to increase EGFR 
phosphorylation. The tdEOS-GRB2 SH2 fusion, like full length GRB2, increased EGFR 
phosphorylation before and after EGF stimulation. Compared to the full length protein however, 
transient expression of this construct resulted in a more pronounced increase in EGFR 
phosphorylation, especially prior to EGF treatment. By contrast, overexpression of the CRK-
GRB2 chimera resulted in a significant increase in p130CAS phosphorylation with only a minor 
increase (less than two fold) in the phosphorylation of EGFR, consistent with its binding 
specificity for p130CAS phosphotyrosine sites (38, 65, 127, 157). 
These results showed that overexpession of SH2 domains could specifically increase the 
tyrosine phosphorylation of their known cellular binding partners. To more directly address the 
SH2 binding specificity of the enhanced phosphosites, we performed far-Western blotting on 
lysates from COS1 cells expressing the various GRB2 constructs and probed with recombinant 
GRB2 and CRK SH2 domains (Figure 2.1 C). Expression of constructs containing the GRB2 
SH2 domain specifically increased GRB2 SH2 probe binding, particularly of a band 
corresponding to EGFR. By contrast, the CRK SH2 probe bound predominantly to the p130CAS 
band in GCG-expressing cells.  
 
GRB2 mediated pY-EGFR enhancement depends on GRB2 concentration and EGFR 
kinase activity 
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Next we assessed the dose dependence of the enhancement of EGFR phosphorylation by 
GRB2 expression. Increasing amounts of cDNA encoding full length GRB2 were transfected in 
COS1 cells and the average GRB2 concentration per cell was then calculated for each dose 
using a recombinant GST-GRB2 SH2 standard (Figure 2.1 D). As expected, EGFR 
phosphorylation increased with GRB2 concentration. As in Figure 2.1 B and C, the effect of 
GRB2 overexpression was not as dramatic in unstimulated serum starved cells (an 
approximately 2-fold increase)  
To explore the relationship between phosphosite flux and SH2-mediated phosphosite 
protection, we modulated EGFR kinase activity in SH2-overexpressing COS1 cells and 
monitored EGFR phosphorylation. Cells were transfected with tdEOS-GRB2 SH2 or the tdEOS-
GRB2 SH2 R86K mutant and then treated with increasing concentrations of EGF (Figure 2.1 E). 
Relative EGF-induced increases in phosphorylation were fairly constant between 0 and 2.5 
ng/mL EGF (5-7 fold), but fell off at higher EGF concentrations and eventually plateaued. The 
absolute increase in phosphorylation (difference between mutant and wild type GRB2 pY-EGFR 
signal at a particular EGF concentration) peaked at 2.5 ng/mL EGF, and dropped off at both 
higher and lower concentrations. Quantification using a phosphospecific antibody for EGFR 
pY1068, an established GRB2 binding site, revealed similar results (Figure 2.1 E).   
 
Specificity of SH2-dependent phosphotyrosine enhancement 
If SH2 domains enhance phosphorylation by protecting their binding sites from 
dephosphorylation, then protected sites should be enriched for high-affinity sites containing  
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Figure 2.1: Effect of GRB2 expression in EGF-stimulated COS1 cells. A) Diagram of major 
constructs used for this study: tdEOS tagged GRB2 SH2, full length wt GRB2 and a chimera of 
GRB2 SH3 domains and the CRK SH2 domain (GCG). B) GRB2-mediated enhancement of 
EGFR phosphorylation is SH2-dependent. Western blotting of lysates from COS1 cells 
overexpressing GRB2, tdEOS-GRB2 SH2 and GCG constructs before and after stimulation with 
2.5 ng/ml EGF. R86K constructs are mutants that are unable to bind phosphotyrosine sites. C) 
Far-Western blotting and immunoblotting of lysates from COS1 cells transfected with GRB2 
constructs. In labels on right, “CRK FW” and “GRB2 FW” indicate far-Western blotting with CRK 
and GRB2 SH2 domains. D) Western blot showing the effect of GRB2 expression level on 
EGFR tyrosine phosphorylation. GRB2 expression levels were determined using a GRB2-SH2 
standard and a GRB2-SH2-specific antibody. Densitometric quantification of this data is plotted 
on the right. E) Western blot showing the effect of EGF stimulation on GRB2-mediated 
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enhancement of total EGFR pY and EGFR pY1068 (a GRB2 SH2 binding site). “GRB2 SH2M” 
is the R86K mutant. Densitometric quantification of this data is shown to the right. 
phosphorylation for seven EGFR phosphosites. In control (empty vector) cells, pY1148 
dominated EGFR phosphorylation, a finding consistent with recent quantitative MS analyses 
(111). Cells expressing each of the three constructs displayed increased EGFR phosphorylation 
at all of the measured sites to varying degrees. Relative to the overall increase in 
phosphorylation of EGFR, as measured by anti-pY immunoblot, both wt GRB2 and tdEOS-
GRB2 SH2 expression resulted in increased phosphorylation of the canonical GRB2 binding site 
pY1068 (EpYINQ), but had an equal or even greater effect on pY974 (FpYRAL), pY992 
(EpYLIP), and pY1173 (EpYLRV). Nevertheless, GRB2 overexpression did result in a significant 
change in the absolute phosphorylation landscape of EGFR in transfected cells, with pY1068 
phosphorylation nearly equaling that of pY1148 (Figure 2.2 A, adjacent bar graphs). As in 
previous experiments, GCG increased total EGFR total phosphorylation by less than two fold. In 
these cells, phosphorylation was significantly shifted in favor of pY992 (EpYLIP), a canonical 
CRK binding site; which was increased more than 10 fold when compared to EGF-treated 
empty vector controls (Figure 2.2 A, adjacent bar graphs).   
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canonical motifs for the overexpressed SH2 domains (e.g. pYXN motifs for GRB2). To test this, 
we transfected three constructs (tdEOS-GRB2 SH2, full length GRB2, and GCG) in COS1 cells 
and monitored the absolute level of phosphorylation at each EGFR site (with and without 
treatment with 2.5 ng/ml EGF) using phosphosite-specific antibodies (Figure 2.2 A). To compare 
signal levels across multiple antibodies we created a maximally phosphorylated pY-EGFR 
standard by treating COS1 cells with 200 ng/mL EGF and the phosphatase inhibitor 
pervanadate for 40 min (Figure 2.2 A, far right lane). Using this method we quantified the 
percent 
Quantitative phosphotyrosine MS analysis of COS1 cells expressing the same four constructs 
revealed similar results (Figure 2.2 B and C, Table 2.1). Overexpression of GRB2 SH2 and full 
length GRB2, and to a much lesser extent the GCG construct, resulted in a generalized 
increase in the relative abundance of the four EGFR phosphosites identified (pY974, 1086, 
1148 and 1173) both before and after EGF stimulation (Figure 2.2 B). Unlike pY-EGFR 
immunoblotting, MS data suggested that tyrosine phosphorylation of EGFR pY974 was only 
mildly increased by exogenous GRB2 expression. All five of the p130CAS phosphopeptides 
identified contained the canonical CRK SH2 binding motif, pYDXP. Of these, phosphorylation of 
four was enhanced by GCG chimera expression (Figure 2.2 C). 
 
The specificity of GRB2 SH2-mediated phosphosite enhancement is concentration 
dependent  
While Western, FW and MS data were broadly consistent with the hypothesis that SH2 domains 
protect their preferred binding sites from dephosphorylation by phosphatases in vivo, the 
specificity was rather modest compared with that seen using peptide-based in vitro interaction 
assays. However, most of our experiments were performed using high intracellular  
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Figure 2.2: Site-specific increases in EGFR phosphotyrosine in SH2-overexpressing cells. A) 
Anti-pY and phosphosite-specific anti-pY-EGFR Western blots from COS1 cells transfected with 
empty vector, tdEOS-GRB2 SH2, FL GRB2 SH2, or GCG. EGF+Pervanadate (200 ng/mL EGF, 
100 μM pervanadate, 40 min) was used as a maximally phosphorylated standard and run with 
the site-specific blots at a 1:10 dilution on the same membranes. Antibodies are indicated to the 
left; for phosphospecific antibodies, numbers indicate phosphosite recognized. The percent 
maximal phosphorylation for each site and total pY-EGFR without (top) and with (bottom) EGF 
stimulation is shown in the bar graphs to the right. B) The relative increase in abundance of 
EGFR phosphopeptides detected by quantitative phosphotyrosine specific mass spectrometry in 
COS1 lysates from cells expressing the SH2 constructs. C) The relative increase in abundance 
of p130CAS phosphopeptides detected as in B. Error bars for B and C represent standard error 
of the mean (SEM). 
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Figure 2.3: GRB2 specifically enhances its canonical binding motifs in a concentration-
dependent manner. A) EGFR pY-specific Westerns from COS1 cells expressing an increasing 
amount of GRB2. EGFR pY amino acid position and pY motifs are indicated on the right. B) 
Quantification of EGFR pY site-specific phosphorylation following EGF stimulation plotted 
against overexpressed GRB2 concentration.  
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concentrations (approximately 5.5 μM) of SH2-containing constructs in order to maximize the 
effect of phosphosite protection. At such high concentrations, SH2 domains likely interact with 
and protect relatively low affinity sites. To better understand the effect of concentration on 
specificity in our system, we analyzed lysates of cells expressing a range of GRB2 
concentrations by probing with EGFR phosphosite-specific antibodies (Figure 2.3). We found 
that the known high-affinity GRB2 binding sites, pY1068 and pY1086, were selectively 
enhanced at relatively low levels of GRB2 overexpression. By contrast, sites predicted to bind 
the GRB2 SH2 with lower affinity, such as pY974, pY1173 and pY1045, were enhanced only at 
the highest GRB2 concentrations (Figure 2.3 B).    
 
SH2 domain overexpression enhances phosphosites within canonical binding motifs 
across the phosphoproteome    
To delve more deeply into the specificity of phosphosite protection associated with SH2 domain 
expression, we used our quantitative MS data to examine the sequence specificity of SH2-
mediated phosphosite enhancement (128, 157). In total, we identified 118 tyrosine-
phosphorylated peptides from 79 different proteins (Table 2.1). MS analysis indicated that for 
almost half of these phosphopeptides, their abundance was significantly increased or decreased 
in cells overexpressing SH2 domains relative to controls (Figure 2.4 A). In particular, the 
phosphosites enhanced by expression of GRB2 or the GRB2 SH2  were enriched for the GRB2 
SH2 binding motif (pYXN), while GCG-enhanced sites were enriched for the CRK SH2 binding 
site (pYXXP) (Figure 2.4 4B and C). Collectively, the enhanced motifs closely resembled those 
previously identified using in vitro binding assays (see insets in 4B and C) (36). This suggests 
that GRB2 and CRK (i.e. GCG) SH2-mediated phosphosite  
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See attached Excel files 
Table 2.1: iTRAQ MS data and SH2-enhanced phosphosites. MS Data tab lists all 
phosphopeptides identified by MS. The protein name, accession number, peptide sequence, 
relative abundance, and standard deviation of all peptides identified are shown. Peptides 
phosphorylated at serine and/or threonine are listed, but were not included in our analysis. 
Mean abundance values are such that the sum for each peptide equals eight. GCG 
ENHANCED tab lists the proteins, sequence and fold change in abundance for peptides that 
displayed increased abundance in GCG-transfected cells (over empty vector-transfected) for 
both starved and EGF treatment conditions. GRB2 ENHANCED tab lists the protein, sequence 
and fold change in abundance for peptides enhanced in tdEOS-GRB2 SH2 and full length 
GRB2-transfected cells (over empty vector transfected) for both starved and EGF treatment 
conditions. Data from GCG ENHANCED and GRB2 ENHANCED were used to create the 
LOGOs in Figure 2.4 B and C.  
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Figure 2.4: Quantitative MS-based analysis of tyrosine phosphoproteome in cells 
overexpressing SH2-containing proteins. A) Bar graph showing the percentage of 
phosphopeptides in each experimental treatment whose abundance was increased, decreased 
or unchanged. B) Peptide LOGO of phosphosites whose abundance was enhanced by GRB2 
construct expression before and after EGF stimulation. Inset shows peptide LOGO for in vitro 
GRB2 binding phosphopeptides from by Tinti et al. C) Peptide LOGO of phosphosites whose 
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abundance was enhanced by GCG expression both before and after EGF stimulation. Inset 
shows peptide LOGO for in vitro CRK binding phosphopeptides from by Tinti et al. 
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enhancement was largely binding site specific when assessed across the entire 
phosphotyrosine proteome (106). 
 
Computational model of SH2 phosphosite protection 
These results strongly suggested that SH2 domains specifically prevent the dephosphorylation 
of their phosphorylated binding sites in vivo by shielding those sites from being accessed by 
phosphatases. To better understand the behavior of such a system we generated a quantitative 
computational reaction model of SH2-pY interactions in cells before and after EGF stimulation 
and compared model predictions with experimental data (Figure 2.5) (106).   
To generate an accurate and realistic model, we experimentally determined as many 
parameters as possible in our COS1 cell system (Table 2.2). In particular, we quantified EGF-
dependent and -independent phosphorylation and dephosphorylation rates at steady state in the  
absence or presence of EGF. Absolute rates were quantified by quantifying anti-pY 
immunoblots of lysates from cells treated with the tyrosine phosphatase inhibitor pervanadate 
before and after EGF stimulation, and from EGF-stimulated cells treated with the EGFR kinase 
inhibitor Erlotinib, using an absolute standard for phosphotyrosine developed in our lab (Figure 
2.5 B-D) (50, 142). The independently obtained measures of EGFR phosphorylation and 
dephosphorylation in EGF-treated cells were nearly identical as would be expected of a system 
at steady state. EGFR phosphorylation was modeled as a first order substrate-limited reaction, 
as we were unable to obtain reasonable Vmax values by fitting to the Michaelis-Menton equation. 
EGFR dephosphorylation was modeled by fitting dephosphorylation data (i.e. Erolotinib 
treatment) to the Michaelis-Menton function. The phosphorylation rate constant (kf) and 
dephosphorylation Vmax and Km values were calculated using the measured rates, and the 
percent pY-EGFR values obtained in Figure 2.2. Phosphorylation in unstimulated cells was  
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Figure 2.5: Computational model and parameter determination. A) Diagram of the 
computational model used to quantify the effect of SH2 expression on EGFR phosphorylation. 
The effect of SH2 domain expression in unstimulated cells utilized the same scheme, but used 
an EGFR kf value obtained in unstimulated cells. B-D) Measurement of in vivo phosphorylation 
and dephosphorylation rates in COS1 cells. B) Plot of absolute phosphorylation rate in serum-
starved cells treated with pervanadate. C) Plot of absolute phosphorylation rate in starved cells 
treated with pervanadate five minutes after stimulation with 2.5 ng/mL EGF. D) Plot of absolute 
dephosphorylation rate in cells treated with Erlotinib five minutes after stimulation with 2.5 
ng/mL EGF. Black lines show amount of phosphorylation quantified from experimental data. 
Red lines show initial rate used to calculate model parameters. pY-EGFR concentrations were 
obtained by comparing anti pY Westerns of COS1 lysates with a recombinant v-Abl-derived 
phosphotyrosine standard. E) Plot of experimental data for fraction of total pY-EGFR (orange 
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circle) and EGFR pY1068 (blue square) overlaid on model predictions generated at varying kon 
values. Plots were created by holding the koff constant at 1 s-1 and varying kon values (black 
lines).  
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Table 2.2: Model Parameters. All parameters were defined using experimental data unless 
otherwise noted below. Cell volumes were approximated from measurements of trypsinized 
cells. EGF binding constants were taken from the literature. COS1 cell phosphorylation and 
dephosphorylation rates were measured by comparing changes in phosphorylation under three 
conditions with a v-Abl-derived phosphotyrosine standard (see Figure 2.5 B-D). Measurements 
of in vivo EGFR phosphorylation rates and approximations of EGFR expression in COS1 cells 
were used to calculate the EGFR kf values. Phosphatase Vmax and Km values were obtained by 
fitting the quantitative EGFR dephosphorylation data to the Michaelis-Menton function. GRB2 
concentrations were calculated via Western blotting using a purified GRB2 standard run on the 
same membrane. GRB2 binding constants were determined using data from previously 
published work and by fitting experimental data to the model (See Figure 2.5 E). *= Berkers 
1991, ψ=French 1995, Ω= Oh 2012.  
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modeled using the same reaction kinetics scheme, and the assumption that all EGFR kinases 
present in the cell had the same basal activity and contributed to substrate domain 
phosphorylation. EGFR and EGFR substrate concentrations were estimated using published 
estimates of EGFR expression in A431 cells and anti-EGFR Westerns comparing EGFR 
expression in COS1 and A431 cells. EGF concentrations are those used experimentally. EGF-
EGFR binding parameters were previously published and used to define the percent of active 
EGFR kinases (99, 100, 158).  
The GRB2 SH2-pY-EGFR dissociation constant (koff) was obtained from recently published in 
vivo measurements (94). Binding (kon) and dissociation (Kd) constant values were then 
approximated by fitting our experimental GRB2 titration data (see Figure 2.1 D) for both total 
pY-EGFR and pY1068 to modeling data generated using different kon values (Figure 2.5 E). The 
resulting Kd values, approximately 1.0 and 0.66 μM respectively, are near the average of 
measurements for GRB2 SH2-pY interaction generated from solid phase assay (~0.2-0.7 μM) 
and solution methods (2.6 μM) (43, 89, 159, 160).   
 
Comparison of modeling and experimental data 
Using the GRB2-pY-EGFR Kd value of 1 μM, we then modeled the effect of increasing 
concentrations of EGF on phosphosite abundance (Figure 2.6 A). The size of the effect 
predicted by the model closely matched experimental results, with increasing EGFR kinase 
activity significantly suppressing the relative effect of SH2 domain-mediated protection.  
We then tested the effect of increasing GRB2 concentrations on EGFR phosphorylation using 
our computational model. Maximal percent phosphorylation was similar to that found 
experimentally; EV+EGF at ~5.0% and GRB2 SH2+EGF at ~20% (Figure 2.6 B and 2.2 A). 
Closer examination of the data revealed that GRB2 SH2-mediated increases in total 
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phosphorylation did not greatly affect the number of unbound sites within the system. Even at 
GRB2 concentrations twenty times that of the endogenous protein, resulting in a greater than 
four-fold increase in total phosphorylation, the number of unbound sites decreased only by 
approximately 25% (Figure 2.6 B). This minimal reduction in free phosphosites suggested that 
protection might minimize the effect of competition between SH2 domains with similar substrate 
specificities. 
To more directly assess this hypothesis we added a GRB2 competitor SH2 to our model, 
referred to here as SH2competitor. We set the binding affinity of SH2competitor for 
phosphorylated EGFR equal to that of GRB2, varied its concentration, and monitored the 
amount of GRB2 bound to EGFR (Figure 2.6 C). The model predicted that a 60-fold increase in 
the amount of SH2competitor resulted in only a 22% decrease in the amount of GRB2 bound to 
EGFR. We surmised that the surprisingly modest effect of excess competitor depended on the 
turnover of phosphosites, which in turn drove protection of SH2-bound sites from 
dephosphorylation. For comparison, we modeled GRB2-EGFR binding in a system that 
contained the same initial amount of EGFR pY, but did not allow for pY turnover mediated by 
kinase and PTP activity (Figure 2.6 C). In this system, the addition of a similar amount of 
SH2competitor resulted in a nearly 84% decrease in the amount of GRB2 bound to EGFR.   
To test effect of SH2 competition on downstream signaling in vivo, we assessed the 
phosphorylation of ERK1 and ERK2, well established effectors of EGFR activation, in cells 
transfected with tdEOS-GRB2 SH2 (66). Overexpression of tdEOS-GRB2 SH2, which lacks the 
GRB2 SH3 domains and cannot itself contribute to downstream signaling, resulted in an 
approximately 25% reduction in the phosphorylation of ERK1 and ERK2 (Figure 2.6 D). These 
data are consistent with our model predictions, as well as with a recent report showing that 
overexpression of a GFP-tagged GRB2 construct with an artificially enhanced phosphosite  
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Figure 2.6: Computational modeling recapitulates experimental data. A) Comparison of model 
predictions (red bars) and experimental data (green bars) assessing the relative effect of EGF 
concentration on GRB2 SH2-mediated EGFR phosphosite enhancement. See Figure 2.1 E. 
Error bars represent the standard error of two technical replicates. For modeling data, the GRB2 
concentration was set at 5.4 μM (maximum expression by transfection) B) Model predictions of 
the relationship between SH2-bound phosphosites (pY-SH2, orange) and unbound 
phosphosites (pY, blue). C) Model predictions showing the effect of an increasing concentration 
of a GRB2 binding site competitor (SH2competitor) on the amount of pY-bound GRB2. Dark 
green bars represent pY-GRB2 binding in a system with pY flux (i.e. phosphorylation and 
dephosphorylation; Figure 2.5 A). Light green bars represent pY-GRB2 binding data in a system 
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containing a constant 3.6% pY EGFR (equal to the amount of pY present in the Flux model 
without any SH2 present). D) Quantification of phosphorylated ERK1 (dark blue) and ERK2 
(light blue) in COS-1 cells expressing tdEOS GRB2 SH2 before and after EGF stimulation. All 
values are normalized to empty vector-transfected unstimulated cells and total ERK expression.  
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affinity, but not GFP-tagged wt GRB2 SH2, suppressed the growth of EGFR-expressing cell 
lines in an anchorage independent growth assay (161).  
 
Discussion 
Phosphosite protection by SH2 domain containing proteins is a familiar concept within the field 
of phosphotyrosine signaling, but has not been rigorously investigated to date. Seminal 
experiments exploited this phenomenon to identify specific SH2 binding sites in vitro, but its 
occurrence and importance in vivo are less understood. (146, 147, 151). Here we present a 
focused study of this phenomenon using the EGFR-GRB2 interaction as a model.   
The results of our work suggest that GRB2 overexpression can lead to enhanced 
phosphorylation of EGFR in an SH2- and dose-dependent manner. Replacement of the GRB2 
SH2 domain with the CRK SH2 domain resulted in a shift in protection from EGFR to the focal 
adhesion protein p130CAS, an established CRK SH2 binding protein, suggesting that 
enhancement depended on SH2 binding specificity (157). The observed enhancement of 
specific binding sites was concentration-specific. Expression of GRB2 at concentrations close to 
the GRB2-EGFR dissociation constant resulted in high specificity for enhancement of canonical 
GRB2 binding motifs on EGFR; by contrast, very high concentrations of GRB2 (between 4 and 
6 μM) enhanced the phosphorylation of both canonical and non-canonical binding sites. This 
loss of specificity is likely due to increased binding to lower affinity sites as the SH2 
concentration increases. Alternatively, SH2 binding might prevent dephosphorylation of 
unbound phosphorylated sites by sterically preventing phosphatase access. It been suggested 
that no more than three SH2-containing proteins can bind to EGFR at once (49). In this 
scenario, as GRB2 SH2 concentration increases and binding nears saturation, phosphorylation 
of unbound sites increases because they are less accessible to cellular phosphatases even as 
they remain unbound. 
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Analysis of the tyrosine phosphoproteome by MS revealed enhancement in the expected 
canonical SH2 binding motifs for the GRB2 and CRK SH2 domains (Fig. 4B and C), consistent 
with a mechanism dependent on SH2-mediated phosphosite protection. While our experiments 
mostly identified known interaction partners for the SH2 domains tested, this approach may be 
useful to identify interaction partners for SH2 domains with more poorly defined specificities, 
particularly those which are difficult to purify for use in in vitro studies (36, 38, 162). 
Furthermore, this method would allow for the identification of interactions that occur in vivo, in 
the cell type of choice. For this purpose it would be significantly simpler than alternative 
methods utilizing inducible covalent binding or biotinylation, which require mutation and 
optimization of SH2 domains (90, 91). 
To better understand the basis for SH2-mediated phosphosite protection, we created a 
compartmental deterministic ordinary differential equation (ODE) model using the Virtual Cell 
reaction modeling software (106). An important feature not previously incorporated into models 
was experimentally determined steady state phosphorylation and dephosphorylation rates. We 
determined these values using a method we recently developed to quantify the absolute amount 
of phosphotyrosine in a sample (50). While not done in this study, this approach could be 
combined with percent phosphorylation and receptor concentration data to determine to 
absolute rates of phosphorylation and dephosphorylation for individual phosphosites.  
Model predictions recapitulated experimental data quite accurately, indicating that phosphosite 
protection is sufficient to explain increased receptor phosphorylation upon SH2 domain 
overexpression in our system. Arguably, a more complex model incorporating  rule-based 
modeling and multiple phosphorylated sites might provide more detailed insight into the system 
(163). However, the simplicity of the model used in here makes it much more flexible for 
application to other systems. For instance, our lab and others have previously shown that the 
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SH2 domain of CRK appears to prevent p130CAS tyrosine dephosphorylation (164, 165). This 
could easily be modeled, using similar methods to quantify protein amounts and 
phosphorylation levels. 
One rather counterintuitive prediction from the model is that phosphosite protection reduces 
competition between SH2 domains with overlapping specificities. Due to SH2-mediated 
phosphosite protection, output from one SH2-containing effector can increase or decrease 
depending on the local concentration of that SH2, without greatly affecting output from other 
SH2-containing effectors with similar binding specificity. In this way SH2 signaling through a 
specific pY motif is additive, if the following three conditions are met. First, SH2 domains in the 
system must bind similar pY sites. As mentioned above, most SH2 binding motifs fall into 
several broad classes, suggesting that significant specificity overlap exists (37, 166). Second, 
phosphatase activity must be high and as a result most potential phosphosites must be 
unphosphorylated. Consistent with this, previous studies showed that the stoichiometry of 
tyrosine phosphorylation was low both in starved and stimulated cells (167). This is also 
demonstrated by the dramatic increase in tyrosine phosphorylation seen after treating cells with 
the phosphatase inhibitor pervanadate (Figure 2.5 B and C).  
The final requirement is that SH2 domains have moderate affinities for their phosphotyrosine 
binding sites, so that binding is not saturated at intracellular concentrations. Recent work that 
exploited protein structure data to develop high-affinity SH2 domains suggests there is selective 
pressure to maintain moderate affinities (161). In vitro affinity measurements showed that Kd 
values for SH2-EGFR interactions largely fall between 0.8 and 4 μM, with each phosphosite 
interacting with multiple SH2 domains (89, 168). Of course there are a few examples of SH2-pY 
interactions with high affinities, which may have evolved to drive specific signaling pathways 
and eliminate significant SH2-dependent signaling cross-talk (169, 170). 
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Phosphosite protection may also play an important biological role in oncogenic signaling. SH2 
proteins that are largely unbound at normal expression levels may behave very differently when 
highly overexpressed. Viral CRK (v-CRK) and its human homolog CRKI are able to transform 
fibroblasts, despite consisting of only an SH2 and SH3 domain. Presumably these CRK proteins 
exploit phosphotyrosine flux on their binding proteins to create their own binding sites through 
protection, allowing them to induce excess signaling through pro-growth pathways (64, 151). 
Likewise, the SH2 containing adaptor GRB7 is often overexpressed in breast cancers 
overexpressing the orphan RTK and EGFR family member HER2. GRB7 overexpression is 
associated increased HER2 phosphorylation, which results in activation of pro-oncogenic 
downstream pathways and increases in cell growth and migration (171, 172). The relative lack 
of SH2 competition associated with phosphosite protection may also allow for cancer cells to 
maintain homeostatic signaling processes in the setting of increased expression of oncogenic 
SH2-containing proteins such as SRC, BCR-ABL, JAK, or STAT.  
Finally, it is important that phosphosite protection be considered both in experimental design 
and data interpretation. For example, recently published work has shown that SHCD 
overexpression results in a significant increase in phosphorylation of EGFR in a PTB-dependent 
manner. The largest increases occurred at the SHCD PTB binding site, pY1148, and to a lesser 
extent at pY1068 and pY1173 (154). Although this study does not consider protection from 
phosphatases as a potential explanation for the findings, the data are highly consistent with this 
mechanism. More generally, fluorescently tagged SH2 domains and SH2-domain containing 
proteins are sometimes used as probes in vivo to monitor the availability of binding sites for their 
endogenous counterparts (94, 157). The data presented here suggest that SH2-only probes 
would only marginally affect binding of endogenous proteins, and therefore can be used as 
tracers of SH2-pY interactions in vivo without significantly disrupting signaling. On the other 
hand, isolated SH2 domains have also been used as dominant negative reagents, in principle 
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blocking signaling from phosphosites by preventing binding of endogenous, wt proteins that 
normally bind that site (173–177). Our work shows that such dominant negative approaches will 
typically not be effective unless expression levels are extremely high, as at more moderate 
expression levels significant unbound phosphosites remain. 
Taken together, the work presented here suggests that phosphosite protection is an inherent 
characteristic of the phosphotyrosine signaling system in vivo. This feature may allow a specific 
pY site to provide both homeostatic signaling and a diverse set of cell-type specific SH2-
mediated signaling outputs at the same time. The process is also likely an important feature of 
signaling through other dynamic post-translational modifications (PTMs) including 
serine/threonine phosphorylation and lysine acetylation, both of which can signal through 
modular reader domains in manner closely resembling SH2-pY interactions. Thus, a complete 
understanding of signaling from these and other writer-eraser-reader systems requires 
consideration of the innate ability of reader proteins to participate actively in the signaling 
process. 
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Abstract 
Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in the United States and 
around the world.  Approximately 70% of all NSCLC tumors contain an activating mutation in 
either the receptor tyrosine kinase (RTK) EGFR or the small GTPase RAS.  Furthermore, 
dysregulation of signaling by RTKs, the RAS family of proteins and their downstream effectors 
has been shown to be essential for the growth of a number of tumor types.  Specifically, 
elevated levels of EGFR phosphorylation due to receptor mutation or overexpression are known 
to induce cellular transformation.  Recent data from our laboratory and others have shown that 
expression of the constitutively active RAS family mutant, KRASV12, results in reduced EGFR 
phosphorylation in NSCLC cells (178–180).  Our preliminary data suggest that these changes to 
EGFR phosphorylation are mediated by protein-tyrosine phosphatases (PTPs), a relatively 
understudied family of proteins which function in opposition to tyrosine kinases by 
dephosphorylating tyrosine residues which prevents the binding of downstream effector 
proteins.  We hypothesize that KRAS drives a previously undescribed feedback pathway which 
enhances the activity EGFR targeting PTPs. 
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Introduction: 
Over the past twenty years there has been a concerted effort by the scientific and clinical 
communities to apply our understanding of the basic molecular biology of cancer to develop 
therapies that specifically target selected molecular pathways that drive tumor growth, with a 
particular emphasis placed on inhibitors of tyrosine kinases and their downstream effectors 
(181, 182).  Effective application of these new cancer treatments requires an in depth 
understanding of how each target protein fits into the web of interconnected molecular signaling 
pathways (183).  Of particular importance is understanding the role potential drug targets play in 
regulating important upstream signaling hubs through negative feedback.  
The Epidermal Growth Factor Receptor is an excellent example of such one such signaling hub, 
as it has multiple downstream effectors, many of which are potential targets for drug 
development.  As outlined in the Introduction to this thesis, EGFR activation by EGF leads to 
reciprocal phosphorylation of a set of tyrosine residues on the C-terminal tail of the paired 
receptor.  Each phosphotyrosine residue is then capable of recruiting a unique set of SH2 
domain containing adapter proteins and enzymes to EGFR at the membrane where they 
propagate the signal to their downstream effectors. These effectors include KRAS, as well as a 
number of other proto-oncogenes and important signaling proteins that promote cell 
proliferation, motility survival and differentiation (66, 184).  
KRAS, which belongs to the RAS family of small GTPases, is constitutively activated in nearly 
30% of all cancers and 30% of NSCLCs, as result of an activating missense mutation in either 
codon 12 or 13 (the common mutant KRASV12 being used here). This mutation prevents 
conversion to the inactive form of KRAS resulting in continuous mitogenic signaling through the 
RAS-RAF-MEK-ERK pathway (185). Interestingly, activation of these two genes is almost 
always mutually exclusive indicating an antagonistic relationship between EGFR and KRAS.    
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Figure 3.1: SH2 profiling of NSCLC cell lines.  A subset of KRASV12 expression cell lines 
display a unique SH2 binding signature and a relatively low overall tyrosine phosphorylation.  
Red box indicates the KRASV12 cell subset, labeled with “3”.  The cell line with the light gray 
box was initially identified as KRAS mutant negative, but was later shown to express the 
constitutively active form of the NRAS. Figure adapted from Machida et al 2010. 
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A recent study published by our lab using SH2 domains to profile the global phosphorylation 
state of large set of NSCLC cells lines suggested that NSCLC lung cancer cells lines expressing 
KRASV12 displayed a unique global phosphotyrosine signature, including suppressed EGFR 
phosphorylation (Figure 3.1)(67). Previously published quantitative MS and KRAS knockdown 
experiments performed using NSCLC cell lines also suggested that KRAS activation was 
associated with the suppression of EGFR phosphorylation (178, 186).  Here we present 
preliminary data suggesting that KRASV12 expression suppresses EGFR phosphorylation by 
enhancing EGFR dephosphorylation through a PTP mediated mechansim.   
 
Results 
Exogenous KRASV12 expression suppresses EGFR phosphorylation  
To explore the relationship between KRASV12 expression and EGFR phosphorylation we 
created KRASV12 expressing NSCLC cell lines (H322, H2172).  KRASV12 cell lines displayed 
both increased KRAS expression and KRAS activity as measured by activated RAS pulldown.  
Both KRASV12 cells and their mock controls had very low levels of phosphorylation in serum 
starvation conditions.  However, when these cells were stimulated with 2.5ng/mL of the EGF for 
5 min, we observed a significant decrease in the phosphorylation of EGFR in the KRASV12 
cells, as measured by anti-pY antibody (Figure 3.2).        
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Figure 3.2 Exogenous expression of KRASV12 in NSCLC cell lines suppresses EGFR 
phosphorylation.  Stable KRASV12 or empty vector expressing H322 and H2172 cell lines were 
created by retroviral infection and drug selection.  Cells were serum starved overnight and 
stimulated with EGF.  KRASV12 expression resulted in a significant reduction in phospho-
EGFR.  KRAS activity in each line was assessed by Ras-Binding-Protein pulldown and are 
shown in the bottom panel.  
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KRASV12 mediated suppression of EGFR phosphorylation is not the result of receptor 
internalization 
One of the major mechanisms by which EGFR is regulated is via receptor internalization (19, 
187). Activation and autophosphorylation of the receptor leads to the recruitment of the ubiquitin  
E3 ligase Cbl, an SH2 domain containing protein (see Figure 1.2).  Receptors can be 
internalized through both clathrin-dependent and clathrin-independent processes, which have 
been shown to occur between 10 and 60 minutes after receptor activation. Internalized 
receptors are sorted through the endosomal sorting complex and either recycled and sent back 
to the membrane or trafficked to the lysosome for degradation.  
There is some evidence suggesting that KRAS activation stimulates receptor internalization 
(188).  In an effort to rule out this possibility we compared the amount of EGFR at the plasma 
membrane in KRASV12 and empty vector expressing cells.  Cells were treated with Sulfo-NHS-
SS-Biotin, a membrane impermeable biotin conjugate which forms disulfide bonds with 
accessible lysine residues on surface proteins. The cells were then lysed and biotinylated 
proteins were pulled down using avidin beads.  Both the mock and KRASV12 H2172 cell lines 
had similar levels of membrane associated EGFR (Figure 3.3). This suggested that the 
observed decrease in EGFR stimulated EGFR phosphorylation was not the result of KRAS 
driven receptor internalization and that other mechanisms should be explored. 
 
KRASV12 enhances the rate of EGFR dephosphorylation 
The level of tyrosine phosphorylation on any protein is a function of the balance between kinase 
and phosphatase activity and potentially the concentration of pY binding proteins (see Chapter 
2).  To examine the role of kinase activity in the KRASV12 associated decrease in EGFR 
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phosphorylation, we measured the basal rate of EGFR phosphorylation in cells with and without 
the constitutive KRAS by experimentally eliminating phosphatase activity using pervanadate.  
When EGFR kinase activity was isolated in serum starved mock and KRASV12 cells using 
pervanadate no difference in total receptor phosphorylation or the phosphorylation rate was 
observed, suggesting that KRASV12 was not somehow suppressing the EGFR kinase (Figure 
3.4).   
We then examined the effect of KRASV12 overexpression on the rate of EGFR 
dephosphorylation. EGFR targeted PTP activity was isolated by suppressing EGFR kinase 
activity using the TKI Erlotinib (42). Interestingly, we found a nearly 4 fold increase in the rate of 
dephosphorylation in H2172 cells expressing the KRAS mutant (Figure 3.5).  These results 
suggest that KRASV12 expression enhances the activity or expression of PTPs acting on 
phosphorylated EGFR.    
 
KRASV12 may suppress the growth NSCLC cells driven by constitutive EGFR activation 
If KRAS activation does in fact suppress EGFR phosphorylation, this might explain why 
activating mutations in these proteins are rarely ever observed together in clinical samples. By 
suppressing EGFR phosphorylation and the resultant downstream signaling, KRASV12 might 
reduce cellular fitness compared to cells expressing the EGFR mutant alone. To examine this 
interesting correlation, we created a KRASV12 expressing cell line using HCC827 cells, an 
NSCLC cell line which expresses a constitutively active form of EGFR.  Unlike non-mutant 
EGFR cell lines, KRASV12 expressing HCC827 cells did not display a noticeable difference in 
receptor phosphorylation (Figure 3.6 A). However, when we assessed the rate of EGFR 
dephosphorylation in these cells, we observed a noticeable increase in cells expressing 
KRASV12, similar to that seen in wild-type EGFR cells. (Figure 3.6 B). 
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Figure 3.3: Membrane localization of EGFR in KRASV12 cells. Extracellular and 
transmembrane proteins on unpermeablized H2172 KRASV12 and empty vector cells were 
biotinylated using NHS-S-S-Biotin at 4oC prior to lysis. Biotinylated proteins were isolated with 
avidin labeled beads, run on SDS-PAGE and immunoblotted for EGFR.  No difference in total 
EGFR or membrane bound EGFR was observed suggesting that decreased EGFR 
phosphorylation in KRASV12 cells is not a result of increased receptor internalization.  
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Figure 3.4 Quantification of basal EGFR kinase activity in KRASV12 cells. H2172 cells infected 
with empty vector (ev) or expressing KRASV12 were starved overnight, treated with 100nM 
pervanadate, lysed at the times shown and run on SDS-PAGE. No difference in basal EGFR 
phosphorylation rate was observed indicating that the EGFR phosphorylation rate was 
unchanged by KRASV12 expression. Y-axis values are non-normalized densitometry 
measurements.  
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Figure 3.5: Quantification of EGFR dephosphorylation rate in KRASV12 expressing H2172 cells. 
Serum starved H2172 KRAV12 and empty vector cells were stimulated with 25ng/mL EGF for 
10 min (-600 min).  At the 10 minute point cells were treated with 10uM of the selective EGFR 
TKI Erlotinib, flash frozen at the times shown, lysed and immunoblotted using an antibody which 
specifically recognizes EGFR pY1173 (top panel).  The EGFR dephosphorylation half-time was 
nearly 4 times shorter in KRASV12 expressing cells. Phosphorylation half-time values were 
determined by fitting each data set to an exponential decay function (bottom panel).  Calculated 
half-times for each cell line are shown to the left of the graph. KRASV12 cells-red dots.  EV 
cells-blue dots.   
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To assess the functional effect of KRASV12 expression on EGFR driven cell growth we 
compared the monolayer culture growth rate of the two cell lines using MTT assay.  Over a 
period of 144 hrs no difference in growth was observed (Figure 3.7).  However, most cells lines, 
both untransformed and transformed, grow rapidly in monolayer culture and as a result subtle 
differences in cellular growth may not be apparent.  To more thoroughly assess the differences 
in cell transformation associated with the expression of both mutations, we the performed an 
anchorage independent growth assay.  This method, also known as a soft agar assay, is a 
classic measure of cell transformation, in which cells are grown suspended in Bacto-agar 
prepared using cell culture media.  Interestingly, using this method we observed, a nearly 10% 
decrease in the total number of colonies (p=0.21) and a 25% decrease in colony size 
associated with KRASV12 (p=0.11) (Figure 3.8 A-C). While these differences were not 
statistically significant they do suggest that KRAS signaling might suppress EGFR driven tumor 
growth.              
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Figure 3.6: Effect of KRASV12 on EGFR dephosphorylation in HCC827 cells driven by a 
constitutively active form of EGFR. A) Western-blots showing EGFR phosphorylation and 
KRASV12 expression in KRASV12 and empty vector HCC827. B) Dephosphorylation curves 
obtained by treating starved HCC827 cells with 10uM Erlotinib. Data did not fit the exponential 
decay function. However, direct measurements of curves suggest that the half-time of EGFR 
pY1173 is approximately 3 times lower in KRASV12 expressing cells. KRASV12 expressing 
cells were also dephosphorylated to a lower level (last time points). Empty vector cells are 
shown in red. KRASV12 cells are shown in blue.  
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Figure 3.7: Monolayer cell growth of KRASV12 and empty vector expressing HCC827 cells.  
Plot showing the relative change in KRASV12 and empty vector cell number over 144 hrs in 
monolayer growth.  Reduction of the tetrazolium dye MTT by cellular oxidoreductases was used 
as a proxy for total cell number and measured by absorbance.  First time point values for both 
cell lines were are normalized to 1.  Results represent average of three technical replicates.  
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Figure 3.8: Anchorage-independent growth of KRASV12 and empty vector expressing HCC827 
cells. A) Representative image of colonies from KRASV12 and empty vector cells. B) 
Quantification of average colony number for each cell line. C) Quantification of average colony 
size for each cell line (inches2).  Statistical analysis - Student’s t-test. n= number of biological 
replicates.      
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Discussion: 
As evident from the work presented so far in this thesis, regulation of receptor tyrosine kinase 
phosphorylation can occur at multiple levels.  The work presented here suggest that elevated 
KRAS signaling leads to increased phosphatase activity which in turn suppresses EGFR 
phosphorylation.  Expression of the constitutively active KRASV12 resulted in a decrease in 
EGFR phosphorylation, which was most prevalent following EGF stimulation.  This effect 
appears to be a PTP mediated process, as receptor dephosphorylation occurred much more 
rapidly in KRASV12 expressing cells.   
From a basic biological perspective KRAS mediated negative feedback is rational. Excessive 
EGFR signaling can lead to aberrant cell growth and eventually cellular transformation.  By 
initiating downregulation of receptor phosphorylation, KRAS may prevent unopposed pro-
growth, anti-apoptotic signaling. Interestingly, this is not the first example of KRAS induced 
phosphatase mediated regulation. KRAS activation has been shown to stimulate phosphatase 
mediated negative feedback of activating serine and threonine phosphorylation on mitogen 
activated protein kinases (MAPKs) activation.  This process is mediated by dual-specificity 
phosphatases (DUSPs), capable of acting on pS and pT, as well as pY(189). While no DUSP 
has been shown to dephosphorylate EGFR, further inquiry into DUSPs as a potential mediator 
of the observed findings may be warranted.   
While invoking a new role for DUSPs in EGFR signaling regulation is an interesting hypothesis, 
classical PTPs are the most likely drivers of our findings.  A number of PTPs, including PTPN9, 
RPTPκ and RPTPη have been shown to dephosphorylate EGFR (190–192). However, 
identification of the specific PTPs involved in KRAS mediated EGFR dephosphorylation remains 
a difficult task due, at least in part, to the general lack of PTP substrate specifity.   A recently 
developed method for identifying and quantifying a cell’s specific PTP expression (PTPome) 
and PTP activation state (oxizided PTPome) may provide some insight in the specific PTPs 
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involved (193).  While a preliminary assessment of the PTPome suggested that no large 
difference exists in PTP expression between these KRASV12 and empty vector cell lines (data 
not shown), a more in depth analysis of PTP expression and activity using both western and 
mass spectrometry could provide more insight.  
Although the current results are still equivocal, our studies of KRASV12 expression in mutant 
EGFR driven NSCLC cells suggest that a PTP mediated process may contribute the clinical 
mutual exclusivity observed between KRASV12 and activated EGFR. These finding are 
particularly interesting because they suggest that oncogene induced transformation is a 
measured process, where more is not always better.  RAS activation or expression might be 
tempered in order to maintain optimal signaling through all EGFR mediated pathways.   
However, further analysis of the interaction between the two processes is needed. It is also 
worth noting that the absolute level of phosphorylation in the presense or receptor specific 
inhibitors was lower in KRASV12 cells.  This may be the result EGFR phosphorylation by non-
EGFR TKs which is also suppressed in KRASV12 expressing cells.  
Finally, the work presented here only examined total EGFR phosphorylation and EGFR pY1173.  
KRASV12 expression may lead to the dephosphorylation of specific phosphosites on EGFR.  
Understanding the effect on each site will be essential to understanding how different 
downstream pathways are affected. Moreover, it behooves us to examine the effect of 
KRASV12 expression on the phosphorylation status of other proteins, including other RTKs.   
The anti-pY blots in figure 4.2 suggest that this process may not be EGFR specific, but instead 
may be the result of a generalized increase in cellular PTP activity.   
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Summary 
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The work presented here examines the regulation of phosphotyrosine signaling on three 
different levels using the Epidermal Growth Factor Receptor as a tool to understand universal 
properties of pY signaling systems. These include temporal changes in receptor localization and 
phosphorylation, the effect of SH2 protein expression on maintenance of tyrosine 
phosphorylation and the role of negative feedback from downstream effectors.   This work only 
touches on the plethora of known regulatory mechanisms known control signaling from this 
important oncogene. Nevertheless, our hope is that the mechanisms presented herein will have 
a much wider impact on how researchers in the field understand and approach phosphotyrosine 
signaling on the whole.   
We begin with a general overview of pY signaling, the protein families involved, the specific 
proteins assayed and the different methodological approaches used.   The introduction 
highlights the importance of approaching phosphotyrosine signaling as a dynamic process in 
which the flux of phosphotyrosines is dependent on kinase and phosphatase activity, as well the 
specificities and concentrations of specific SH2 domains.  We focus on the utility of SH2 
domains as a Domainomics tool to assess phosphotyrosine dependent signaling.  Information 
about the orthogonal methods and techniques utilized in subsequent chapters are also 
discussed.  
Chapter 1 follows with a large scale investigation into the spatial and temporal regulation of 
EGFR activation and SH2 binding.  Here we compare phosphotyrosine and SH2 binding 
dynamics on three different levels; tyrosine phosphosite dynamics assayed by quantitative MS, 
SH2 binding site dynamics assayed by FW and SH2 domain membrane recruitment and binding 
in vivo assayed by live cell membrane imaging. The work, which was performed on a global 
scale includes: a temporal analysis 100 unique pY sites by MS, SH2 binding dynamics following 
EGF stimulation for 27 domains and 22 time points, and an in vivo analysis of membrane 
recruitment and diffusion values for 25 different SH2 domains. The most important finding from 
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this work was that SH2 recruitment to the membrane is delayed in comparison to SH2 site 
availability, which occurs rapidly in response to EGF. These findings indicated that SH2 
membrane recruitment is not in equilibrium with pY site creation.  Deconvolution of in vivo 
binding data suggested that this finding may be due to binding site clustering at the membrane.  
As clustering progresses in response to EGF stimulation, the likelihood of SH2 membrane 
rebinding increases. This means the rate at which SH2 domains leave the membrane 
decreases.  As a result, SH2 recruitment continues to increase until SH2 binding sites have 
clustered. In all, this research both adds to a growing body of work the supporting role of spatial 
organization in regulating protein signaling and highlights the importance of challenging one’s 
own results using orthogonal methodologies.  
Chapter 2 focuses on the role SH2 domain containing proteins play in maintaining their own 
binding sites.  This work revisits the concept of SH2 mediated phosphosite protection, a 
hypothesis derived from early the results of early in vitro studies, verifying and quantifying its 
effects in vivo.  We exploit the well studied interaction between pY-EGFR and GRB2 to quantify 
role of SH2 concentration and kinase activity on binding site protection.  The specificity of 
GRB2-SH2 mediated enhancement is assessed on two levels. First in relationship to the 
specific tyrosine sites on EGFR using traditional biochemical methods and then in relation to the 
entire proteome using quantitative MS.  Finally, we recapitulate our protection results using 
computational reaction modeling, incorporating concentrations and reaction rates obtained by in 
vivo measurements (using live cells as opposed to recombinant proteins).  Finally, using both 
computational and biochemical assays we propose a model in which competition between SH2 
domains from different proteins with shared specificities is relieved by the ability of SH2 
domains to maintain their own binding sites via protection for phosphatases. If this theory holds 
true it suggests that increased binding of effectors does not necessarily significantly decrease the 
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amount of unbound sites available.  This would mean that signaling output from multiply 
phosphorylated proteins such as EGFR is an additive process and not a zero sum game.  
Chapter 3 concludes with preliminary data from an investigation into the role KRAS signaling in 
inducing EGFR dephosphorylation. This paper builds on data published by our lab suggesting 
that KRAS signaling drives changes in the global phosphotyrosine landscape.  Using NSCLC 
cell lines stably expressing the constitutively active KRASV12 mutant we demonstrated that 
elevated KRAS activity is associated with a significant reduction in EGFR phosphorylation.  We 
then showed that this finding is associated with an increase the rate of EGFR 
dephosphorylation.  We hypothesized that this negative interaction might contribute to the 
mutual exclusivity observed between EGFR and KRAS in almost all tumor types. To begin to 
assess this hypothesis, we stably expressed KRASV12 in a NSCLC cell line containing an 
activating EGFR mutation.  EGFR phosphorylation was not suppressed in these cells, however 
we did were observe an increase in the EGFR dephosphorylation rate.  Anchorage independent 
growth in these cells also trended lower, but the difference was not statically significant.  
Together these results support a mechanism by which KRAS negatively feeds back on EGFR 
by altering the kinase-phosphatase balance within the cell.  
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Future Directions 
  
 127 
 
Chapter 1  
Assess the variations in EGFR phosphosite phosphorylation dynamics. 
EGFR far-Western and phosphosite specific Western blotting suggested that small but 
significant differences exist in the relative rate of phosphorylation at different EGFR 
phosphosites.  These differences may represent an innate mechanism for regulating signal 
output from the receptor following stimulation.  In order to understand this process more fully we 
propose quantifying the phosphorylation of specific EGFR phosphosites in response to 
variations in EGF concentration, using different EGFR ligands (e.g. EGF, TNF- and 
amphiregulin), and in cells expressing different EGFR concentrations (160, 194).  The latter 
experiments would be best performed in a single cell line, such as A431 cells, with variable 
levels of EGFR knockdown.  It may also be possible to quantify the relative phosphorylation of 
specific sites under specific conditions using a pY-EGFR standard as described in Chapter 2.  
By integrating this data we may be able to create topological maps of EGFR signaling output in 
response varying conditions.  
 
Compare phosphorylation dynamics and SH2 binding for p130CAS using optimized MS 
protocol 
The orthogonal analyses of SH2 binding sites (i. e. phosphosites) performed in Chapter 1 
identified a number of inconsistencies between the phosphorylation dynamics quantified by FW 
and MS.  Of particular note, was the phosphorylation of p130CAS, a highly phosphorylated focal 
adhesion protein which contains number pYXXP, CRK binding sites (65). Blot based analyses 
of p130CAS phosphorylation following EGF stimulation have always suggested that p130CAS is 
rapidly dephosphorylated in response to EGFR activation (195). MS based experiments have 
been less clear, often returning few peptides and may be confounded by the repetitive CRK 
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binding sequences found within the p130CAS substrate domain. (3).  The iTRAQ MS analysis 
performed in Chapter 1 identified five p130CAS phosphosites, but failed to demonstrate the 
dephosphorylation observed by FW and pY immunoblot.  One potential explanation for this 
discrepancy is that phosphosites on p130CAS are differentially phosphorylated in response to 
EGF, with some sites dephosphorylated and others remaining flat or even increasing in 
response to EGF.  This hypothesis is consistent with the fact that FW analysis of phospho-
p130CAS identified some SH2s with level or even increased binding following EGF treatment.  
Our MS analysis may have been skewed toward identifying these sites.  In an attempt gain a 
more complete understanding of p130CAS phosphosite dynamics we propose performing a 
p130CAS-specific analysis using both FW and MS.  Assay sensitivity may be improved by 
precipitating and concentrating p130CAS from EGF treated lysates prior to protease treatment.  
We also propose running the MS analysis using nontraditional proteolytic agents such as 
elastase or chymotrypsin along with trypsin, which was employed in our initial experiments in 
order to increase the likelihood of detecting sites that were missed in our analysis of tryptic 
peptides. 
 
Quantify SH2 membrane recruitment and rebinding with induced receptor clustering.  
The in vivo imaging and pervanadate treatment experiments presented in Chapter 1 provide 
strong evidence for delayed recruitment as a cluster dependent process.  However, these 
results do leave room for alternate explanations.  Validation of our proposed mechanism would 
require that we monitor SH2 membrane recruitment under specific controlled levels of receptor 
clustering.  Light inducible clustering using Cry2-RTK chimeras provide a mechanism to do just 
this. Cry2 is a photoreceptor protein isolated from Arabidopsis which rapidly and reversibly 
multimerizes in response to blue light.  Cry2 chimeras have been used to study the clustering in 
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a number of RTKs including TRK, FGFR, and PDGFR. Using one of these established proteins 
or a new Cry2-EGFR chimera, along with TIR and sptPALM imaging, it should be possible to 
directly assess the effect of clustering on SH2 membrane recruitment and binding.     
 
Model SH2 membrane recruitment to clustered receptors using Langevin modeling. 
As mentioned above, the role clustering plays in the recruitment of SH2 domains to binding sites 
on the membrane should be further validated using more controlled methods. One way to do 
this is by modeling the process computationally.  Typical reaction modeling solvers such as 
those used in the Virtual Cell (see Chapter 2) are do not treat molecules as space filling objects 
and are therefore may not be appropriate for modeling the effects of receptor clustering.  On the 
other hand molecular modeling, which does take molecular volumes into account, is highly 
computationally intensive, making it difficult to use for dynamic processes involving multiple 
copies of different proteins such as SH2 domains binding to clustered, phosphorylated 
receptors. In an effort to find some modeling middle ground, Dr. Paul Michalski, a former 
member of the CCAM modeling team, designed a general purpose Langevin dynamics 
simulator that models proteins as a set of sites connected by stiff links. The sites are modeled 
as impenetrable spheres, which captures the effects of excluded volume and steric hindrance.  
Using this simulator software, it should be possible to model the recruitment of SH2 domains to 
phosphorylated receptors at the membrane with variable levels of clustering.  This would allow 
us demonstrate the role of membrane phosphosite rebinding and its effects on recruitment 
within a tunable system containing a defined set of species (i. e. SH2 and EGFR with binding 
sites).    
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Chapter 2 
Evaluation SH2 phosphosite protection as a method for identifying SH2 binding 
motifs/binding partners for SH2 domains which are insoluble as recombinant proteins. 
In our attempt to verify that the GRB2 SH2 domain was enhancing EGFR phosphorylation by 
protecting its binding sites, we assessed GRB2 SH2 associated changes across the entire 
phosphoproteome.  To do this we compared the relative abundance of individual phosphosites 
in cells with and without exogenous SH2 expression.  Using this method we were able to show 
that the SH2 domains used (GRB2 and CRK) were enhancing sites containing their canonical 
binding motifs.  While these motifs have been validated by a number of previous in vitro binding 
experiments, the binding specificities of a number of SH2 domain families has not been 
assessed due to the poor solubility and/or pY-binding performance of their recombinant 
proteins. These include RIN, STAT and JAK family SH2 among others. However, we have 
expressed some of these SH2 domains in eukaryotic cells as GST-fusion proteins including 
those of JAK2, STAT2 and SOCS2  (data not shown).  We propose using in vivo pY protection 
coupled with MS quantification to define pY binding motifs for such domains.  The method would 
also likely identify new binding partners for these domains, which could then be verified by more 
traditional methods such as immunoprecipitation. 
 
Utilize the newly developed Vcell hybrid modeling solver create a more complete model 
of EGFR activation and phosphosite protection. 
Though the model used in Chapter 1 was able to recapitulate our in vivo data and using 
quantified parameters, it is still a fairly simplistic model of EGFR signaling. It contains only a 
single EGFR phosphosite, treats EGFR as a monomer and treats EGFR kinase and substrates 
domains as individual species. These assumptions were made largely to simplify the model for 
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our purposes. For instance, adding new phosphosites to a substrate domain can rapidly 
increase the total number of reactions required to complete a model. When an additional 
phosphosite is added to a partial differential equation model, reactions for the substrate domain 
in each of its four possible phosphorylation states must be defined for any interaction involving 
the receptor.  Rule-based modeling can reduce this combinatorial explosion, by defining the 
interactions that can occur and the sequence in which they occur (163, 196).  Until recently this 
process required that these rules be defined using a specific nonintuitive coding language, 
which itself is somewhat opaque to individuals without a background in modeling or computer 
coding.  However, a more biologically intuitive interface is currently being developed using the 
VCell platform which combines both rule-based and partial differential equation modeling.  Most 
importantly though, this software attempts to treat molecules, PTMs and interactions in a 
graphical manner that is more intuitive to the typical biologist.  This software should allow for the 
development of an EGFR-SH2 interaction model capable of incorporating multiple phosphosites 
and multiple SH2 domain containing proteins. Moreover, by applying the methods developed in 
Chapter 2 for absolute phosphotyrosine quantification, site specific percent phosphorylation and 
quantification of kinase/phosphatase rates, it should be possible create an accurate model of 
EGFR phosphorylation dynamics for a specific cell type.  This might help us understand why, for 
instance, the GRB2 SH2 domain appears to protect noncanonical pY motifs on EGFR.  It could 
also allow us to quantify the apparent in vivo dissociation constants of specific SH2 domains, 
such as GRB2 SH2 for noncanonical pY motifs.          
 
Test the protection model using a non-pTyr system 
The protection model proposed in Chapter 2 was only validated using the reader, writer and 
eraser proteins involved in pTyr signaling. However, there is no reason that the mechanism of 
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reader dependent post-translational modification protection should be limited to this pTyr 
signaling. Serine and threonine phosphorylation, lysine acetylation and arginine/lysine 
methylation, each have their own set of reader proteins.  For instance, bromodomain (BRD) 
containing proteins bind acetylated lysine residues on histone tails. 61 BRD containing proteins 
have been identified and a significant body of research suggests that their affinity for any 
particular histone tail is highly dependent on the post-translational modification (methylation, 
serine/threonine phosphorylation) of nearby residues (197).  This suggests that, as with SH2 
domains, BRD specificity is both diverse and overlapping. It seems reasonable to suggest that 
BRDs protect their binding site acetyl groups from the activity of histone deacetylatases. 
Maintenance of specific histone marks could profoundly affect local transcriptional activity.  
Interestingly, this mechanism has been invoked in the literature to explain the ability of BDF1 
BRDs to maintain euchromatin in yeast (198).  It therefore seems reason to expand our study of 
protection into other modular domain containing proteins and in particular BRDs.  By using 
methods such as chromatin immunoprecipitation, DNase protection and transcriptome 
sequencing to assess the affect of isolated BRDs and full length protein expression on local and 
global changes in histone acetylation, secondary histone PTMs and transcription patterns, we 
might gain insight into the innate properties of these domains and the role they play in regulating 
transcription. 
 
Chapter 3 
Assess EGF induced EGFR phosphorylation in KRAS (or a generalized RAS) knockdown 
cell line 
The preliminary data presented in Chapter 3 suggests that constitutive KRAS activity 
suppresses EGFR phosphorylation by upregulating PTP activity.  It is difficult to know if this 
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feedback is part of the normal signaling pathway, or if it is specific to KRASV12 signaling.  As 
such it would be useful to assess the phosphorylation of EGFR in cells expressing varying 
levels of wild type KRAS. For example, EGFR phosphorylation in shRNA mock knockdown cells 
should be lower than in KRAS (or pan RAS) knockdown cells. These experiments could also 
provide some information about the temporality of this KRAS mediated response.  If the 
feedback occurs through cytoplasmic signaling alone, one might expect EGFR phosphorylation 
in mock cells to display pY signal attenuation immediately following stimulation (minutes to 
hours). However, if no difference is observed, it is more likely that the mechanism requires 
transcription level changes.   
 
Assess the EGFR phosphorylation/dephosphorylation in response to other RAS family 
proteins. 
The RAS family of small GTPase, (ie. KRAS, NRAS, HRAS) share a high level of sequence 
homology.  However, a  body of research suggest that they are not entirely interchangeable, 
with each performing a unique function in cellular transformation (199, 200).  In order to better 
understand the connection between RAS signaling and phosphatase activity we propose 
repeating our KRAS experiments using the constitutively active mutants of NRAS and HRAS.   
While it is difficult to quantitatively compare the activity and effects of the different mutants, it 
would be useful to know if phosphatase activation and EGFR dephosphorylation is a general 
feature of RAS signaling.  
 
Identify KRAS effectors which mediate phosphatase regulation 
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Our current data strongly point to a connection between KRAS and phosphatase activity. 
However, the signaling pathways linking these two remains a black box. To establish a 
molecular connection between KRASV12 and EGFR dephosphorylation, we propose assessing 
EGFR phosphorylation in cells in which the activity of well established KRAS effectors (i. e. 
PI3K, AKT, MEK, and PKC δ) have been manipulated. A combination of commercially available 
inhibitors, RNAi and constitutively active mutant overexpression could be used to identify 
proteins directly involved in our findings.  It may also be useful to look for any direct KRASV12-
PTP interactions by performing KRAS immunoprecipitation followed by PTPome analysis (anti-
oxidized PTPome western on pervanadate treated lysates).  
 
Assess the specific phosphorylation sites affected by KRASV12 induced EGFR 
dephosphorylation. 
One of the major questions yet to be resolved in this work is the specificity of KRASV12 
mediated phosphatase activity.  Substrate specificity has been observed for some PTPs and 
therefore it is reasonable to believe that KRASV12 activated phosphatases may target specific 
sites on EGFR.  The relative changes in phosphorylation at each EGFR pY site should be 
assessed using the phosphospecific antibodies utilized in Chapters 1 and 2.  It would also be 
useful to quantify these site specific effects in a number of cell lines demonstrating KRAS 
associated EGFR dephosphorylation, as differential phosphorylation in a single cell line could 
have many explanations, including differential SH2 protein expression and EGFR phosphosite 
protection. 
 
Determine if the activation of any other receptors (or other phosphoproteins) is 
suppressed by KRAS activation 
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In addition to EGFR phosphosite specificity we are also interested in the protein specificity of 
KRASV12 driven phosphatase activity.  Is the effect specific to EGFR family proteins, RTKs or a 
generalized increase in activity?  A quantitative phosphospecific MS study of phosphosite 
abundance in KRASV12 cell identified very few proteins, aside from EGFR, which are 
dephosphorylation in KRASV12 expressing cells (186). However, this work only examined EGF 
associated phosphorylation.  By expressing our KRASV12 construct in cell lines expressing 
other RTKs (i. e. FGFR, HER2, PDGFR andMET) or other proteins with high levels of 
phosphorylation (i. e. p130CAS, FAK, paxillin, ABL, SRC) we should be able to assess the 
extent to which KRAS regulates tyrosine phosphorylation.  In addition, it would also be useful to 
perform FW blotting on lysates from these cell lines using a few representative SH2 probes (e.g. 
GRB2, CRK, PI3K).  This would allow us to detect changes in specific phosphosites on multiply 
phosphorylated  proteins without having to acquire phosphosite specific antibodies for each 
protein.  Moreover, by integrating protein and SH2 specific data we may be able to gain greater 
insight into the phosphatases involved, the mechanism by which they are being regulated and 
the signaling pathways which are being targeted. 
 
Quantify PTP activity in KRASV12 expressing cells using PTPome MS-based analyses 
Potential mechanisms by which KRASV12 drives EGFR dephosphorylation include altering PTP 
localization, activity or expression.  In order to address the latter two possibilities we propose 
assessing PTP expression (PTPome) and oxidation-associated PTP inactivation (oxPTPome) in 
our KRASV12 and mock cell lines using a recently published protocol which exploits an 
antibody that recognizes the oxidized active site of all PTPs (193).  Differentially regulated PTPs 
can be detected by western blotting and specifically identified by MS.  If KRASV12 regulated 
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PTPs are identified, PTP-specific RNAi can then be employed to assess the role of these PTPs 
in EGFR dephosphorylation.  
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Introduction 
The Domainomics section of this Introduction section is adapted from the published review  J.  
Jadwin, M. Ogiue-Ikeda, K. Machida, The application of modular protein domains in proteomics. 
FEBS Lett. 586, 2586–96 (2012), on which I am the first author.  All other text and figures in this 
section is my own original work.  
 
Chapter 1 
The work presented in Chapter 1 is an unpublished manuscript prepared by the authors listed 
below the title.  The manuscript text was prepared by me, B. Mayer, J. Yu and T. Curran, with 
editing assistance and scientific input from K. Machida, D. Oh and F. White. Construct 
preparation was performed by M. Ikeda and preliminary experiments were performed by L. Jia 
and K. Machida.  MS phosphopeptides identification was performed by T. Curran. All imaging, 
image analyses and image quantification (excluding immunofluorescence) were performed by 
D. Oh.  FW blot quantification was performed by K, Machida and I. All other experimental work, 
analyses including and manuscript preparation including; western, FW, immunodepletion, cell 
culture, peptide analysis, GO analysis, immunofluorence preparation, manuscript figure layouts, 
and interactive chart preparation were performed by me.  The research was supported by the 
National Cancer Institute Grant U01CA154966 (to B.J.M. and F.W.) and partly supported by a 
Quest for CURES (QFC) grant from the Leukemia and Lymphoma Society (to K.M.). We would 
like to thank Michael Blinov for assistance with the SH2:Mem equations and Ahmed Elmokadem 
for assistance with immunofluorescence imaging.  
 
Chapter 2 
Chapter 2 is an unpublished manuscript prepared by me and edited by B. Mayer.  MS peptide 
identification and quantification was performed by T. Curran. B. Mayer cloned the GCG 
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construct. All other work presented here was performed by me. I would like to thank J. Yu for 
productive discussions related to reaction kinetics and modeling. 
 
Chapter 3 
Chapter 3 is preliminary data and text for an unpublished manuscript.  Text preparation and 
experiments were all performed by me with editing assistance and scientific input from B. 
Mayer. 
 
Summary and Future Directions  
Summary and Future directions sections were prepared by me with editing and input from B. 
Mayer.  I would also like to thank Adam Lafontaine for useful discussions on modeling and 
receptor clustering experiments.  
 
All other text, figures and experiments not specifically attributed in the this Contributions 
sections can be were prepared and performed by me with editing assistance and suggestions 
provided by by B. Mayer.  
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Chapter 1: 
SH2 domain expression constructs: Characteristics of SH2 domain constructs used in this study 
are provided in Table 1.1. GST-SH2 probes for far-Western were cloned in pGEX backbones as 
previously described (38) and are available through Addgene at 
https://www.addgene.org/Bruce_Mayer/. SH2-tdEOS clones were generated using Gateway 
cloning as previously described (94). 
Antibodies and reagents: Anti-pY immunoblots and immunofluorescence experiments were 
performed using mouse monoclonal pY100 (CST, #9411). EGFR was detected using rabbit anti-
EGFR (SCBT, #sc-31157) and monoclonal rabbit anti-EGFR (CST, #4267) and 
immunoprecipitated using rabbit anti-EGFR sepharose beads (CST, #5735). p130CAS was 
detected using mouse anti-p130CAS (BD, #610274) and immunoprecipitated using agarose 
beads conjugated with mouse anti-p130CAS (SCBT, #sc-20029). GAB1 was detected using 
mouse anti-GAB1 (Milipore, #06-579) and immunoprecipitated using the same antibody bound 
to Protein A sepharose CL-4B beads (GE Healthcare, #17-0780). SHCA was detected using 
rabbit anti-SHC (SCBT, #288) and immunoprecipitated using mouse anti-SHC (Thermo 
Scientific, #47F4) bound to Protein G agarose beads (Life Technologies, #20398). Phospho-
SHCA was detected using rabbit anti-phospho-SHC pY317 (CST, #2431). EGFR phosphosite-
specific Westerns were performed using the following antibodies: pY845 (SCBT, #sc-575442), 
pY974(CST, #2641S), pY992 (CST, #2235P), pY1045 (CST, #2237P), pY1068 (CST, #3777P), 
pY1086 (CST, #2220S), and pY1173 (CST, #4407S). Antibodies against pY1148 (CST, #4404S 
and Thermo Scientific, #44-792G) and pY1101 (Abcam, #ab76195) were tested but returned 
low signal to noise. GRB2 SH2-tdEOS and GST-GRB2-SH2 were detecting using mouse anti-
GRB2 SH2 (R&D Systems, #669604). pERK1 and pERK2 were detected using rabbit anti 
p44/42 pT202/pY204 (CST, #9101S). Pervanadate (PV) was prepared fresh for each 
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experiment by mixing 1 vol 100 mM NaVO4 with 0.32 vol 30% (w/w) hydrogen peroxide at room 
temperature (RT) for 30-90 min.  
Sample preparation:  All experiments were performed using the human squamous-cell 
carcinoma line A431. For FW and MS experiments, cells were grown to ~70% confluence in 
standard growth media, starved overnight and stimulated with 25 ng/mL EGF for the appropriate 
duration. Media was then removed and cells were snap frozen via submersion in liquid N2 within 
3 to 5 s. For imaging experiments, cells were plated onto acid-washed glass bottom dishes (< 
50% confluent) (MatTek) and allowed to grow overnight. Cells were transfected with 100-200 ng 
of DNA using 1-3 µl of Lipofectamine 2000 (Life Technologies) in antibiotic-free Opti-MEM (Life 
Technologies). After 4 h, transfection media was aspirated, replaced with complete media and 
cells were allowed to grow overnight. Prior to imaging, DMEM culture media was removed, cells 
were washed with PBS and kept in phenol red minus media (BrainBits). For pervanadate 
experiments, pervanadate was prepared fresh, diluted in culture media and added to cell culture 
dishes at a final concentration of 100-200 M. 
Far-Western and Western blotting: Far-Western blotting was performed as previously described 
(38). Far-Western blotting: Briefly, snap frozen cells were thawed on ice at 4oC, lysed and 
scraped in Kinase Lysis Buffer (150 mM NaCl, 25 mM Tris-HCl pH 7.4, 5 mM ethylene diamine 
tetraacetic acid (EDTA), 1 mM phenyl methyl sulfonyl fluoride (PMSF), 1% Triton X-100, 10% 
glycerol, 0.1% sodium pyrophosphate, 10 mM β-glycerophosphate, 10 mM NaF, 5 μg/ml of 
Aprotinin (Sigma A6279), 50 μM pervanadate), cleared by centrifugation, run on Lithium 
Dodecyl Sulfate (LDS) PAGE using NuPAGE NOVEX 4-12% gradient gels (Life Technologies, 
#WG1403A) and transferred overnight onto nitrocellulose membranes. 30 duplicate membranes 
were created, with all membranes containing positive and negative pY controls. Blots were 
frozen at -20oC, thawed, blocked with 5% non-fat dry milk in Tris pH 8.0 buffered saline (TBST) 
for 1 h and blotted for 2 h with 1-5 ng/ml recombinant GST-SH2 labeled with GSH-HRP and 
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anti-GST-HRP diluted in 5% milk-TBST. Blots were then rinsed with TBST, washed for 20 min 
with two buffer changes and imaged using ECL (PerkinElmer, #NEL104001EA) on the Kodak 
Image Station 4000 MM for 1 h. Reprobing was performed using the procedure outlined above, 
after stripping by washing with 100 mM glycine, pH 2.0 twice for 15 min followed by thorough 
washing with TBST. Blotting was performed at least twice for all quantified SH2 probes. 
Quantified far-Westerns met the following conditions: 1) pY-dependent binding (pervanadate-
treated positive control sample has greater signal than PTP-treated negative control); 2) 
reproducibility for replicate membranes; 3) EGF-dependent changes in band intensity; 4) high 
signal-to-noise (minimal non-specific bands) and 5) high blot quality (minimal background and or 
signal distortion). 67 probes were initially screened for this study. Of these, the SH2 domains of 
BLK, BLNK, BRDG1, BRK, CBLB, CIS1, CSK, CTEN, EMT/ITK, FER, FES, FGR, FRK, GRB10, 
HCK, JAK3, LNK, LYN, P55G(NC), PLCG1(SH2+3), SH2-B, SH3BP2, SHB, SHIP1, SOCS2, 
SOCS3, SOCS4, SRC, STAT1, STAT3, STAT5A, SYK(NC), and ZAP70(NC) and PTB domains 
of CTEN, DOK1, FRS2, IRS1, SHCD, TENC1, and SCK, were excluded due to data quality. It 
should be noted that many of these probes have shown good activity in other systems (38, 67).  
Western blotting: Nitrocellulose membranes were prepared in a manner similar to that outlined 
above for far-Western. Western blotting was performed using standard procedures (blocking in 
5% milk, washes in TBST, overnight primary antibody incubation at 4oC, 1 h secondary antibody 
incubation at RT). Both HRP/ECL and IRDye (680 and 800 nm) labeled secondary antibodies 
were used. Blots were imaged using the Kodak Image Station 4000 MM or Licor Odyssey 
imager as appropriate. 
Protein identification by immunodepletion: SH2 binding proteins were tentatively identified via 
their SH2 binding affinities and molecular weights. Band identities were confirmed by repeated 
immunoprecipitation (3 or 6 times) of EGF-treated lysates using antibody-conjugated beads as 
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listed above, followed by comparison of pre- and post-depletion lysates using the listed 
antibodies for immunoblot.  
SH2 binding band quantification and hierarchical clustering: Briefly, major protein bands of each 
blot were auto-detected and quantified using the Carestream MI software (Carestream) after 
subtracting background. Apparent non-specific bands with low reproducibility in multiple 
experiments were manually excluded. The molecular weight of each band was estimated using 
protein ladder lanes on the both sides of the blot. Hierarchical clustering was performed using 
average linkage and Pearson correlation using Cluster 3.0 software. Heat maps were created 
using Java Treeview software. For kinetics clustering (Figure 1B), all bands were normalized to 
the band with the maximum signal and averaged. For relative specificity clustering, bands from 
each time point (i.e. lane) were normalized to the total signal per lane for all SH2s and 
averaged. The normalized values obtained for pY blots were then subtracted from these 
normalized values on a band-by-band basis.  
Determination of GRB2 SH2 and pY-EGFR concentration: The approximate cellular GRB2 SH2-
tdEOS concentration was determined by comparing GRB2 SH2-tdEOS expression levels in 
transfected A431 cells with a GST-GRB2-SH2 standard of known concentration via immunoblot. 
Briefly, A431 cells (30 mm plate) were transfected with 1μg GRB2 SH2-tdEOS using 
Lipofectamine 2000 (Life Technologies), incubated for 18 h, lysed in KLB, run by LDS-PAGE 
along with a serial dilution of the GRB2 standard, transferred to nitrocellulose and 
immunoblotted with anti-GRB2 SH2. GRB2 SH2-tdEOS transfection efficiency and expression 
level distribution were determined by quantifying epifluorescence images, acquired with a 1.5 
min exposure using a CCD camera, using ImageJ. Average cell volume was calculated from 
three DIC images of non-adhered A431 cells. Cellular pY-EGFR concentrations were calculated 
by comparing pY immunoblots of EGF-stimulated cells with a tyrosine-phosphorylated protein 
standard created in our lab and quantified using a malachite green free phosphate quantification 
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assay (50). A431 cells were plated and EGF-stimulated using the protocol performed for FW 
above. Lysates were run on LDS-PAGE along with a serial dilution of the pY standard and 
immunoblotted using anti-pY. Signal intensity of the 195 kDa EGFR band and the total pY 
standard signal were quantified using Image Studio ver. 4.0 (Licor). The number of 
phosphotyrosines in the standard lanes were calculated and used to create standard curve, 
which was then used to calculate the concentration of EGFR pY residues after correcting for the 
number of cells run per lane and the cell volume.  
Mass spectrometry sample preparation: Samples were lysed with 8 M urea + 1 mM sodium 
orthovanadate and protein yield was quantified by BCA assay (Pierce). Samples were reduced 
with 10 µl 10 mM DTT in 100 mM ammonium acetate pH 8.9 (1 h at 56° C). Samples were 
alkylated with 75 µl of 55 mM iodoacetamide in 100 mM ammonium acetate pH 8.9 (1 h at RT). 
1 ml of 100 mM ammonium acetate and 10 µg of sequencing grade trypsin (Promega, #V5111) 
were added and digestion proceeded for 16 h at RT. Samples were acidified with 125 µl of 
trifluoroacetic acid (TFA) and desalted with C18 spin columns (ProteaBio, #SP-150). Samples 
were lyophilized and subsequently labeled with iTRAQ 8plex (AbSciex) per manufacturer’s 
directions. iTRAQ Channels were designated as follows: 0s-113, 10s-114, 30s-115, 1m-116, 
1.5m-117, 3m-118, 10m-119, 30m-121. 
Immunoprecipitation: 70 µl protein-G agarose beads (Calbiochem, #IP08) were rinsed in 400 µl 
IP Buffer (100 mM Tris, 0.3% NP-40, pH 7.4) and charged for 8 h with three pY-specific 
antibodies: (12 µg 4G10 (Millipore), 12 µg PT66 (Sigma), and 12 µg PY100 (CST)) in 200 µl IP 
Buffer. Beads were rinsed with 400 µl of IP Buffer. Labeled samples were resuspended in150 µl 
iTRAQ IP Buffer (100 mM Tris, 1% NP-40, pH 7.4) + 300 µl milliQ water and pH was adjusted to 
7.4 (with 0.5 M Tris-HCl pH 8.5). Sample was added to charged beads for overnight incubation. 
Supernatant was removed and beads were rinsed 3 times with 400 µl Rinse Buffer (100mM 
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Tris-HCl, pH 7.4). Peptides were eluted in 70 µl of Elution Buffer (100 mM glycine, pH 2) for 30 
min at RT. 
Immobilized metal affinity chromatography (IMAC) purification: A fused silica capillary (FSC) 
column (200 µm ID x 10 cm length) was packed with POROS 20MC beads (Applied 
Biosystems, #1-5429-06). IMAC column was prepared by rinsing, at approximately 10 µl/min, 
with solutions in the following order: 100 mM EDTA pH 8.9 (10 min), H2O (10 min), 100 mM 
FeCl3 (20 min), 0.1% acetic acid (10 min). IP elution was loaded at a flow rate of 2 µl/min. The 
column was rinsed with 25% acetonitrile, 1% acetic acid, and 100 mM NaCl (10 min) and 0.1% 
acetic acid (10 min), both at 10 µl/min. Peptides were eluted with 50 µl 250 mM NaH2PO4 at 2 
µl/min and collected in an autosampler vial. Eluent was acidified with 2 µl of 10% TFA prior to 
loading. 
Liquid chromatography mass spectrometry: Acidified IMAC eluent was loaded onto an Acclaim 
PepMap 100 precolumn (Thermo Scientific, #164705) using an EASY-nLC 1000 (Thermo 
Scientific). Peptides were analyzed on a 1 h gradient from 100% A (0.1% formic acid) to 100% 
B (0.1% formic acid, 80% acetonitrile) spraying through a 50 cm analytical column (New 
Objective, #PF360-50-10-N-5) packed with 3 µm beads (YMC America, #AQ12S03). 
MS data analysis: Thermo .RAW files were searched with MASCOT v2.4 using Proteome 
Discoverer (v1.4). Peptides that appeared in at least two biological replicates were included if 
their MASCOT scores exceeded 15 and they were designated as medium or high confidence by 
Proteome Discoverer. Normalized iTRAQ values for each biological replicate were averaged to 
produce the final dataset (Table 1.2, MS Data). Error is represented as the standard deviation 
(observed in all three biological replicates) or the average deviation (observed in two biological 
replicates). 
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Gene ontology, sequence motif and EGF dependence analysis: Gene ontology (GO) analyses 
were performed using STRING 9.1. Biological Processes GO terms were queried and significant 
terms were identified as those with p-values < 0.05 after Bonferroni correction for multiple 
comparisons. General gene ontology used in the Venn diagram were obtained by GO semantic 
clustering using REVIGO (129). Sequence motif analysis was performed using the 
PhosphoSitePlus sequence logo generator using the frequency change algorithm and pY 
background (62, 201). Previous documentation of EGF dependence was performed by 
comparing our data set with the PhosphositeSitePlus EGF-associated phosphorylation data set 
as of May 2015. 
Apical and basal membrane pY quantification: A431 cells were grown to ~30% confluence in 
glass bottom 30 mm dishes and starved overnight in 0.1% FBS, 1% pen/strep DMEM. Cells 
were stimulated with 25 ng/mL EGF, quickly washed once in 4oC PBS and fixed with 4% 
paraformaldehyde on ice for 20 min (~15 s media-to-fix time). Cells were then washed with PBS 
three times for 5 min each, permeabilized in 1.5% Triton-X PBS for 10 min and washed with 
PBS three times for 10 min each. Dishes were then blocked in 1.5% BSA PBS for 60 min at 
4oC, incubated with anti-pY (1:500 in blocking buffer) for 2 h while rocking at 4oC, washed three 
times for 5 min in PBS, incubated with anti-mouse IgG conjugated with Alexfluor 594 at RT for 2 
h, washed three times for 5 min with PBS, covered with Fluoromount-G and a glass coverslip. 
Confocal microscopy was used to capture z-stacks through cells with significant apical-basal 
separation. Time points (min) and number of cells quantified are as follows: 0 (n=7), 0.08 
(n=20), 0.17 (n=20), 0.5 (n=29), 1 (n=8), 2 (n=21), 4 (n=20), 6 (n=20), 10 (n=20) and 15 (n=20).   
For each cell, multiple line scans through the z-stack were quantified and averaged in both the x 
and y planes and used to plot the change in apical and basal phosphorylation in response to 
EGF.  
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TIRF microscopy and tdEOS photactivation: A manually controllable home-built total internal 
reflection (TIR) microscopy set-up using an Olympus IX81 microscope was used for all single 
molecule and time-lapse imaging. For cytoplasmic or top membrane illumination, TIR angle was 
switched to epi illumination mode using a step motor (Thor Labs, Inc). A co-aligned 488 nm 
Argon ion laser (Melles Griot) was used to excite the population of non-photoactivated tdEOS 
proteins with a green channel filter set. tdEOS photoactivation was performed using a 405 nm 
diode laser (Cube laser system, Coherent). A 532 nm DPSS crystal diode laser (Crystal Laser 
Inc) was used to excite photoactivated tdEOS proteins using a red channel filter set. 
Fluorescence emission was collected using a thermoelectric cooled EM CCD camera 
(PhotonMax, Roper Scientific). Binding and dissociation rate measurements were performed by 
imaging the photoactivated population under red channel illumination (532 nm). The green 
channel (488 nm) was alternatively used to confirm both longer time recruitment kinetics and 
clustering processes as a function of EGF stimulation time.  
Single particle tracking: Time-lapse single molecule videos were used to track individual SH2 
domains and create individual molecule trajectories. Individual diffraction-limited fluorescence 
dots displaying single step fluorescence photobleaching were tracked using the standard cross-
correlation calculation between raw data and Gaussian PSF kerner. The centroid position of 
cross-correlated particles was determined and used to define particle x-y coordinates. Tracking 
over subsequent images was performed based on the nearest neighbor method. The scan area 
used during position tracking of individual molecules from frame to frame was chosen based on 
the estimated diffusion rate of the molecule. To avoid tracking of non-specific fluorescence dots 
appearing within the scan area, we reduced the density of fluorescence particles to 0.1 – 0.05 
/µm2 using red channel illumination of tdEOS proteins. Dimers or small clusters were filtered out 
by size thresholding of correlated particles. Diffusive cytoplasmic-like fluorescence dots 
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occurring in single frames were filtered out by intensity-based thresholding of cross correlation 
images. 
Trajectory analysis: Mean square displacement (MSD) was calculated as a function of time lag 
(n·Δt, n= integer, Δt=frame interval) using all trajectories over 4 frames long. Individual MSD-Δt 
curves were fitted to the normal diffusion equation at a time scale of n = 2 to 3 (202). Diffusion 
coefficients of individual trajectories were used to create distribution histograms from which 
mean diffusion coefficients were determined. 
Fluorescence localization images: SH2-specific fluorescence images were prepared from 
multiple images (50 - 200 frames) using time-lapse videos recorded at 0.1 Hz. Image 
sequences were z-stack projected using the standard deviation projection method in ImageJ 
(NIH) to create an image depicting the spatial distribution of single molecules. Although the 
resolution of SH2 domain clusters generated by this method is relatively lower when compared 
to that of reconstituted sptPALM images, it allowed us to quickly determine the localization 
patterns of SH2 molecules on the membrane.  
SH2 apparent on- and off-rate determination:  The binding rate of GRB2 SH2 was determined 
using multiple sptPALM image sets of newly recruited GRB2 SH2 obtained at 0.1 Hz for 0.8min 
throughout the EGF stimulation time-course. Counting of only newly emerged molecules in each 
video image sequence was performed based on tracking molecular ID. The apparent on-rate 
(on) of GRB2 SH2 was calculated by dividing the number of newly binding molecules by the 
total acquisition time (0.8 min). The apparent membrane dissociation rate constant (off) was 
determined using the same video dataset. The off of individual SH2 molecules was measured 
using their trajectory lengths and is defined as the reciprocal of the SH2 membrane dwell time. 
As the membrane dwell time of all SH2 modules tested here is shorter than the photobleaching 
time tdEOS, off values were calculated  after compensating tdEOS photobleaching (94). All 
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time measures represent time after EGF stimulation. off values presented in Table 1 were 
measured at 40-60 min after EGF stimulation. 
Determination of clustered and non-clustered apparent on-rates: GRB2 SH2 clusters were 
identified by auto-thresholding sptPALM images (ImageJ). Thresholded binary and raw 
sptPALM images were used to characterize the number of clusters, cluster size and intensity 
(ImageJ).  Maximum intensity measurements were used to determine the number of molecules 
in a cluster.  The apparent binding rate of GRB2 SH2 (on) was determined by dividing the total 
number of molecules by the cluster size and acquisition time.  The average on was derived from 
the distribution of individual on for each movie. To obtain the number of newly binding GRB2 
SH2 molecules in non-clustered regions, we subtracted the number of molecules in clusters 
from the number of molecules identified in the region of interest.  
 
Chapter 2 
Plasmids 
The tdEOS GRB2 SH2 construct was cloned as previously described in Chapter 1 (94). The full 
length GRB2 and GCG constructs were cloned into pEBB (173). The GCG construct was 
creating by replacing the GRB2 SH2 domain (AA 58-159) with the chicken CRK SH2 domain 
(AA 1-124).  
 
Antibodies and reagents 
Anti-pY immunoblot experiments used mouse monoclonal pY100 (Cell Signaling Technology 
[CST], #9411). EGFR was detected using rabbit anti-EGFR (Santa Cruz Biotechnology [SCBT], 
#sc-31157). EGFR phosphosite-specific Westerns were performed using the following 
antibodies: pY845 (SCBT, #sc-575442), pY974 (CST, #2641S), pY992 (CST, #2235P), pY1045 
(CST, #2237P), pY1148 (CST, #4404S), pY1068 (CST, #3777P), pY1086 (CST, #2220S), and 
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pY1173 (CST, #4407S). pERK1 and pERK2 were detected using rabbit anti p44/42 
pT202/pY204 (CST, #9101S). Full length GRB2 and GRB2-SH2 were blotted using the GRB2-
SH2 specific antibody mouse anti-GRB2 SH2 (R&D Systems, #669604). The GCG and full 
length GRB2 were detected using a rabbit antiserum raised against GST-GRB2 produced for 
our laboratory. Pervanadate (PV) was prepared fresh for each experiment by mixing 1 vol 
100 mM Na3VO4 with 0.32 vol 30% (w/w) hydrogen peroxide at room temperature (RT) for 30–
90 min.  
.  
.  
Cell culture 
COS1 cells, a fibroblast-like an African Green Monkey kidney cell line, were cultured in 
complete DMEM media (10% fetal bovine serum, 1% penicillin/streptomycin). Overnight serum 
starvation was performed by aspirating complete DMEM and replacing it with starvation DMEM 
(0% fetal bovine serum and 1% penicillin/streptomycin) and incubating for 6-14 hrs.   
 
Plasmid expression 
The tdEOS-GRB2 SH2, full length GRB2, GCG and empty vector constructs were exogenously 
expressed in COS1 cells using Lipofectamine 2000. 10μg of each construct was used for all 
Western experiments except for the GRB2 dose dependence experiments. For MS experiments 
30 μg of each construct was used per 10-cm dish.  
 
GRB2 SH2 concentration quantification 
The approximate cellular tdEOS-GRB2 SH2 concentration was determined by comparing 
tdEOS-GRB2 SH2 expression levels in transfected COS1 cells with a GST-GRB2 SH2 standard 
of known concentration via immunoblot. Briefly, COS1 cells (30 mm plate) were transfected with 
10 μg tdEOS-GRB2 SH2 using Lipofectamine 2000 (Life Technologies), incubated for 18 hr, 
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lysed in KLB, run by LDS-PAGE along with a serial dilution of the GRB2 standard, transferred to 
nitrocellulose and immunoblotted with anti-GRB2 SH2. The average cell volume was calculated 
from three DIC images of non-adhered cells.  
 
Determination of site-specific relative EGFR phosphorylation 
To determine to relative phosphorylation of each EGFR pY site, a maximally phosphorylated 
pY-EGFR control was created by treating COS1 cells with pervanadate (1:1000 dilution) and 
200 ng/ml EGF for 40 min. Lysates from this control were then diluted 1:10, run alongside 
experimental lysates on LDS-PAGE, transferred to nitrocellulose, Western blotted using the site-
specific anti-pY-EGFR antibodies, and quantified by using the LiCOR system. The percent of 
maximum phosphorylation for each site was then determined by comparing its specific western 
signal to that of the maximally phosphorylated standard.  
 
EGFR phosphorylation/dephosphorylation rate quantification 
To determine the basal EGFR phosphorylation rate, COS1 cells were starved overnight. The 
starvation media was then replaced with starvation media containing 100 μM pervanadate and 
cells were flash frozen in liquid N2 after rapid media aspiration at the time points shown.  To 
determine the rate of EGF-induced phosphorylation, the cells were treated with 2.5 ng/mL EGF.  
After 5 min, the EGF media was then replaced with starvation media containing 2.5 ng/mL EGF 
and 100 μM pervanadate, and the cells were flash frozen in liquid N2 as above.  Cells from each 
time course were then lysed in KLB and run on LDS-PAGE along with an increasing 
concentration of the malachite green-quantified pY-ABL standard (50), transferred to 
nitrocellulose and blotted using anti-pY100.  The absolute rate of EGFR phosphorylation was 
then determined using a pY-ABL standard curve and determining the initial slope following 
pervanadate treatment (Fig. 5B, C).  
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To determine the rate of dephosphorylation, the cells were treated with 2.5 ng/mL EGF.  After 5 
min, the EGF media was then replaced with starvation media containing 2.5 ng/mL EGF and 10 
μM Erlotinib and the cells were flash frozen in liquid N2 at the time points shown.  The rate of 
EGFR dephosphorylation was then determined using as described above for the 
phosphorylation rate (Fig. 5D). 
 
Mass spectrometry 
Cells were transfected with 10μg of the constructs listed, stimulated with 2.5ng/mL for 10 min 
and flash froze in liquid N2. Cells were lysed with 8 M urea + 1 mM sodium orthovanadate and 
protein yield was quantified by BCA assay (Pierce). Samples were reduced with 10 µl 10 mM 
DTT in 100 mM ammonium acetate pH 8.9 (1 hr at 56°C). Samples were alkylated with 75 µl of 
55 mM iodoacetamide in 100 mM ammonium acetate pH 8.9 (1 hr at RT). 1 ml of 100 mM 
ammonium acetate and 10 µg of sequencing grade trypsin (Promega, #V5111) were added and 
digestion proceeded for 16 hr at RT. Samples were acidified with 125 µl of trifluoroacetic acid 
(TFA) and desalted with C18 spin columns (ProteaBio, #SP-150). Samples were lyophilized and 
subsequently labeled with iTRAQ 8plex (AbSciex) per manufacturer’s directions.     
 
Protected consensus sequence determination 
The consensus sequence of protected sites was performed using MS data listed in Table 2.1. 
The abundance of each site in empty vector and SH2-containing protein expressing cells was 
compared. Those sites whose abundance was greater than the combined standard deviation of 
the abundance in each experimental point were determined to be significantly enhanced by SH2 
protein expression. Significantly enhanced pY-sites were then compiled for each experimental 
treatment and the abundance of each significantly enhance peptide was weighted using its fold 
increase over its empty vector control. This weighted list was then used create an amino acid 
sequence LOGO plot using the PhosphositePlus LOGO generator by applying the Frequency 
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Change algorithm and the phospho Tyr background settings (62, 201). The consensus LOGO 
for GRB2 was determined using only those pY peptides whose abundance was significantly 
enhanced under all four treatments (i.e. GRB-SH2, GRB FL, GRB2-SH2+EGF, GRB2 FL+EGF). 
For the CRK consensus sequence LOGO, pY-sites enhanced by both treatments, with and 
without EGF, were used. Phosphosite LOGOs for the data from Tinti et al were created using 
sequences from peptides whose binding signal exceeded the average signal by more than two 
SDs (Z score > 2) (36). The PhosphoSitePlus LOGO generator was also used and no weighting 
was applied.  
 
Computational Reaction Modeling 
All reaction modeling was performed using the Virtual Cell version 5.3.17 using the Combined 
Stiff Solver (IDA/CVCODE). All reaction parameters were approximated as listed in Table 2.2. 
Briefly, total cell volume of COS1 cells was calculated from an average diameter of tyrpsinized 
cells (~20μm). The plasma membrane reaction area was approximated as a hollow sphere 
200nm deep, the nucleus was approximated as an internal sphere with a diameter of 10μm and 
the cytoplasmic volume consisted of the remaining volume. The extracellular volume was set at 
4 ml as in our experiments. EGF concentrations were those used in our experiments. EGF-
EGFR forward and reverse bindings constant values were obtained from Berkers et al 1991 and 
French et al 1995 (99, 100). EGFR receptor numbers were estimated using previous estimates 
of EGFR expression in A431 cells and anti-EGFR Western blots of COS1 and A431 cell lysates. 
The EGFR Kf values was determined using the initial phosphorylation rate of EGFR in EGF 
stimulated or non-stimulated COS1 cells treated with pervanadate. The PTP Vmax and Km were 
obtained by fitting data to the Michaelis-Menton function using OriginPro 2017. The GRB2-
EGFR koff value was taken from Oh et al 2012 (94). The GRB2-EGF Kd and kon values were 
determined by fitting experimental data to modeling data using variable kon values.    
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Chapter 3 
Antibodies 
pY, pY EGFR and EGFR were detected as described in Chapter 1 methods.  KRAS was 
detected using the mouse anti-KRAS (Abnova, #H00003845-M01). 
 
Cell Culture  
H2172, H322 and HCC827 lung adenocarcinoma (NSCLC) cell lines were all obtained from Dr. 
Eric Haura of the H. Lee Moffit Cancer as part for a previously published work, who also 
approved their use in these experiments (67).  Cells were cultured in complete RPMI-1640 (10% 
fetal bovine serum, 1% penicillin/streptomycin).  For EGF or pervanadate stimulation 
experiments cells were starved overnight (8-16 hrs) in starvation RPMI-1680 (0.1% fetal bovine 
serum, 1% penicillin/streptomycin). 
 
Retrovirus production and retroviral transduction  
VSV-G psudeotyped retrovirus was used create KRASV12 expressing NSCLC cell lines. 293T 
cells were grown to 70-80% confluency in 10cm cell culture dishes and transfected with 
retrovirus packaging plasmids (pMD.gag-pol –12ug and HCMV - 4ug) and pBABE KRASV1-
24ug using Lipofectamine 2000.  Media from these cells was collected beginning 24 hrs post –
transfection every 4 hrs for 36hrs.  Media was then filtered through a 0.45um syringe driven 
filter. To create the KRASV12 cell lines, cells were incubated in the virus containing for two 
consecutive 24hr periods.  Infected cells were then grown for an additional day and passed as 
necessary.  KRASV12 expressing cells were then selected for by passing them into complete 
RPMI-1640 containing 10ug/mL puromycin and grown for a period of 7day or until non-infected 
controls were had completely detached.  Cells were then transferred to non-selection media, 
grown for an additional week before KRASV12 expression was verified by western-blot.   
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Surface protein biotinylation and pulldown 
Cell surface EGFR was isolated using the Pierce Cell Surface Biotinylation Kit (#89881). Briefly, 
cells were grown in 10cm culture dishes to 85-95% confluence.  Cells were then transferred to 
the cold room, culture media was removied and cells were washed twice with 10mL of cold 
PBS. Wash PBS was removed and 10mL of 1mg/mL Sulfo-NHS-SS-Biotin (prepared fresh) was 
added to each cell culture dish. Cells were set to rock gently at 4oC for 30 min.  Next the 
biotinylation reaction was quenched by washing the cells three times with Quenching Solution 
(0.5% BSA, 50mM Glycine), gently scraped into a 15 mL conical tube (Falcon), spun down at 
500xg, washed with TBS and spun again 500xg. Cells were then lysed in 500uL RIPA lysis 
buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 
mM Tris, pH 8.0) by rotation at 4oC for 1 hr. 20-50 ul of lysate were then taken to be used as 
prebinding lysate for comparison by Western.  Protein concentrations were then determined via 
Bradford Assay and lysate concentration were normalized using RIPA. Lysates were then mixed 
with Neutravidin Beads (Pierce) in a 3:1 lysate to bead ratio and allowed to rotate for 2 hrs at 
4oC.  Finally beads were spun down at 2000 rpm in a microcentrifuge, washed 2x’s with high 
salt RIPA (500mM NaCl) and once with normal RIPA (150mM) and finally boiled in 6x laemelli 
buffer prior to analysis by SDS PAGE.    
 
Phosphorylation rate quantification 
The basal phosphorylation rate of cells with and without KRASV12 expression was performed 
as described in the Chapter 2 method “EGFR phosphorylation/dephosphorylation rate 
quantification”. 
 
Active-RAS pulldown 
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Active-RAS pulldown was preformed as previously describe by Knaus et al (203). Briefly, RAS 
binding beads were prepared by incubating 60 ug of recombinant GST-RAF1 RBD (AA 1-149, 
Ras Binding Domain, Addgene Plasmid 13338) with GSH-sepharose beads (GE Healthcare) 
overnight at 4oC. NSCLC cell lines were lysed with GTPase lysis buffer (50mM Tris-HCL, 10mM 
MgCL2, 200mM NaCl, 1% (v/v) Triton-X100, 5% glycerol (v/v), 1mM NaVO3, 1mM PMSF, 
1mg/mL aprotinin, pH 7.5) for 10 min on ice and cleared by centrifugation at 13,200 rpm for 10 
min.  Lysate protein concentration was determined by Bradford Assay and 500mg of lysate was 
incubated with 40ul of 1:1 with GST-RAF1 RBD GSH beads and incubated at 4oC for 1hr.  
Beads were then washed 3x’s with GTPase Washing Buffer (25mM Tris-HCL, 30mM MgCl2, 
40mM NaCl, 1% Triton-X100 (v/v) and once with GTPase Washing Buffer without Triton.  Beads 
were then spun down and boiled in 6x laemelli buffer prior to analysis by SDS PAGE.    
 
Adherent cell growth (MTT) assay 
HCC827 cell lines were plated at 1000 cells/well in a cell culture coated 96 well plate and 
allowed to attach for 24 hrs. Growth was assay by MTT Assay every day for five days. For each 
time point 10uL of MTT reagent was added to the wells to be measured and allowed to incubate 
in the cell culture incubator for 3 hrs.  100mL of DMSO was then added to each well, to 
soluabalize the reduced MTT reagent crystals and absorbance of each well was measured at 
570 nm.  Background absorbance was subtracted using empty wells for each day.  Absorbance 
values were then normalized in proportion to the Day 1 value for each cell line and plotted in 
Excel.  Three technical replicates were measured for each cell line.   
 
Anchorage-independent growth assay 
Non-cell culture coated 6cm dishes were coated with 2 mL of a base layer agar (10% FBS , 
0.54% Bacto-agar, 1x RPMI-1640).  1x104 cells were then trypsinized and resuspended in a cell 
growth agar layer (10% FBS, 0.396% Bacto-agar, 1x RPMI-1640).  1mL of complete RPMI-1640 
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was then added on above the cell growth agar. Cells were allowed to grow at 37oC in 5% CO2 
for approx. 3 weeks with 1mL of new complete media was added every 4 days.  Cells were then 
stained with Crystal Violet (0.005%), imaged using the Kodak Image Station (see Chapter 1 
methods) and quantified using ImageJ. 
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